<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRENHEP</journal-id>
<journal-title-group>
<journal-title>Journal of Renal and Hepatic Disorders</journal-title>
<abbrev-journal-title>JRENHEP</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2207-3744</issn>
<publisher>
<publisher-name>Troika Publisher</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.63268/jrenhp.v9i2.210</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>

      <title-group>
        <article-title>An update on current clinical pathogenesis, prevention,
and nutritional aspects of nephrolithiasis: a review</article-title>
      </title-group>
    <contrib-group content-type="authors">
<contrib contrib-type="author">
<name>
<surname>Sachan</surname> 
<given-names>Pranjal</given-names></name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="cor1"/>
</contrib> 

<contrib contrib-type="author">
<name>
<surname>Pandey</surname> 
<given-names>Anjali</given-names></name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib> 


<aff id="aff1"><label>1</label>Department of Pharmaceutics, Sanskriti College of Higher Education and Studies, 209111 Bhognipur, India</aff>
<aff id="aff2"><label>2</label>Department of Pharmacology, Shambhunath Institute of Pharmacy, 211015 Prayagraj, India</aff>

</contrib-group>

<author-notes>
<corresp id="cor1"><italic>Author for correspondence:</italic> <email>pranjupsit@gmail.com</email></corresp>

</author-notes>



<pub-date pub-type="epub">
<day>20</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection"><year>2025</year></pub-date>
<volume>9</volume>
<issue>2</issue>
<fpage>1</fpage>
<lpage>21</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>11</month>
<year>2024</year></date> 
<date date-type="accepted">
<day>17</day>
<month>07</month>
<year>2025</year></date> 
</history>
<permissions>
<copyright-statement><italic>Copyright:</italic> The Author(s). Published by Troika Publisher.</copyright-statement>
<copyright-year>2025</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p><italic>License:</italic> This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link></license-p>
</license>
</permissions>



<abstract>
<p>Nephrolithiasis, commonly known as kidney stone disease, is a prevalent 
condition characterized by the formation of hard crystalline deposits within the 
renal system, primarily due to metabolic abnormalities in urinary composition. In 
India, the prevalence of urinary stone disease is estimated to be around 12%, 
with a significant proportion at risk of progressing to renal impairment if left 
untreated. This review explores both pharmacological and nutritional strategies 
for the prevention and management of recurrent kidney stones. A comprehensive 
literature search was conducted using databases such as PubMed and Google 
Scholar, and major publishers including Springer Nature, Bentham Science, Taylor 
&amp; Francis, and Elsevier. Pharmacological interventions such as thiazide 
diuretics, indapamide, allopurinol, and potassium citrate have been shown to 
reduce urinary calcium and uric acid levels, thereby mitigating stone formation. 
In parallel, several medicinal plants, including <italic>Asparagus racemosus</italic>, 
<italic>Virataradigana</italic>, and <italic>Boerhaavia diffusa</italic>, exhibit diuretic and 
antiurolithiatic properties and have shown promising outcomes in traditional 
medicine and preliminary clinical studies. Although the pharmacological agents 
demonstrate well-established mechanisms of action and clinical efficacy, the 
supportive role of herbal remedies offers a complementary pathway, particularly 
in populations with limited access to conventional therapies. However, the 
current body of clinical evidence for herbal therapies remains limited in scope 
and rigor. Thus, while the combined approach of pharmaceutical and plant-based 
interventions offers a comprehensive strategy for reducing stone recurrence and 
preserving renal function, further large-scale, randomized clinical trials are 
necessary to validate these findings and to establish standardized protocols for 
effective nephrolithiasis management.</p>
</abstract>
<kwd-group>
<kwd>Renal stones</kwd> 
<kwd>Calcium oxalate crystals</kwd> 
<kwd>Urinary stones</kwd> 
<kwd>Pharmacological treatment</kwd> 
<kwd>Non-pharmacological treatment</kwd> 
<kwd>Herbal plants</kwd> 
<kwd>Clinical trials</kwd> 
</kwd-group>
</article-meta>
</front>
<body>

   <sec id="S1" sec-type="intro">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Introduction</title>  
     <p>Hard accumulations are made of substances such as salts and minerals called 
kidney stones that form inside your kidneys. They are also known as 
nephrolithiasis, renal stones, or urolithiasis. Kidney stones are most common in 
people between 30 and 60. Men are more impacted than women by discomfort that is 
intense and caused by renal colic, a kidney stone, is expected to affect 3&#x2013;5% 
of women and 10&#x2013;20% of men. Throughout India, 12 percent of persons are 
predicted to develop urinary stones, and then 50% of those situations might lead 
to kidney loss and renal impairment [<xref ref-type="bibr" rid="ref1">1</xref>]. Future kidney stone incidence is 
predicted to rise as a result of lifestyle modifications, food alterations, and 
obesity [<xref ref-type="bibr" rid="ref2">2</xref>, <xref ref-type="bibr" rid="ref3">3</xref>].</p>  
     <p>Kidney stone disease imposes a substantial economic burden, attributed to the 
high costs of medical interventions and productivity loss resulting from work 
absenteeism [<xref ref-type="bibr" rid="ref4">4</xref>]. It is associated with a higher prevalence of raised blood 
pressure, myocardial infarction, as well as chronic kidney disease [<xref ref-type="bibr" rid="ref5">5</xref>, <xref ref-type="bibr" rid="ref6">6</xref>, <xref ref-type="bibr" rid="ref7">7</xref>]. The 
most common Escherichia coli (E. coli) causes urinary tract infections (UTIs), 
accounting for the majority of cases in both community and healthcare settings.</p>  
     <p>There are no preliminary signs of the stone formation. Subsequently, kidney 
stones (acute cramps illness), flank ache (back discomfort), haematuria 
(blood-soaked urine, pulmonary), (urethral disorder), infection of the urinary 
tract, and obstructions to urine flow, and signs of stone disease include 
pyelectasis or pelviectasis (Urinary tract dilation) [<xref ref-type="bibr" rid="ref8">8</xref>].</p>  
     <p>Urolithiasis prevalence has grown internationally in recent decades, with 
figures ranging from 4.7% in Germany, 10.1% in America [<xref ref-type="bibr" rid="ref9">9</xref>]. Stones in the 
bladder have a significant recurrence rate, estimated to be more than 50% after 
ten years. Nephrolithiasis has been linked to an increased likelihood of chronic 
as well as advanced kidney disease, which is probably due to kidney damage 
induced by obstructive kidneys [<xref ref-type="bibr" rid="ref10">10</xref>].</p>  
     <p>The most common kind of stone is calcium oxalate (67%), preceding calcium 
phosphate (17%), uric acid (8%), struvite (3%), as well as cystine (0.4%) 
[<xref ref-type="bibr" rid="ref11">11</xref>]. Urinary stone development is a complicated process that can be influenced 
by metabolic derangements, hereditary variables, anatomical and functional 
abnormalities, and diet is important [<xref ref-type="bibr" rid="ref12">12</xref>]. Dietary composition can influence 
urine dangers oversaturation alongside stone-forming salt, altering the potential 
danger of urinary stone development [<xref ref-type="bibr" rid="ref13">13</xref>].</p>  
     <p>Due to urinary indicators of danger for stone development differing depending on 
the kind of stone, a reliable stone analysis is required before beginning 
particular treatment regimens. Furthermore, the stone patient must have a full 
metabolic examination, which includes a detailed medical history, nutritional 
assessment, and analysis of the stools and blood [<xref ref-type="bibr" rid="ref14">14</xref>]. To lower the likelihood of 
recurring stone development, focused nutritional therapy ought to be customised 
for each individual metabolic risk profile [<xref ref-type="bibr" rid="ref15">15</xref>]. 
</p>  
     <p>Two consecutive 24-hour urine samples are indicated for detecting frequent 
metabolic abnormalities. These abnormalities include hypercalciuria, 
hypocitraturia, hyperoxaluria, and hyperuricosuria. They are also useful for 
recognising dietary risks for kidney stone development [<xref ref-type="bibr" rid="ref16">16</xref>]. Based on dietary and 
metabolic assessments, specific nutritional treatment is generally more effective 
than wide dietary guidelines in avoiding continuous granite construction. The 
purpose of the following narrative examination summarizes current understanding 
about the significance of diet kidney stones.</p>  
   </sec>  
   <sec id="S2">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Urinary system and stones</title>  
     <p>The glomerulus creates urine filtrate, which eventually goes through the 
tubules, whereby reabsorption or secretion alter the volume and content. The 
previously proximal tubules absorb the majority of solutes, whereas the distal 
tubules, including collecting ducts, make little changes to urine composition.</p>  
     <p>The necessary components, including protein, amino acids, bicarbonate, calcium, 
phosphate, and potassium, are all reabsorbed either returned to the body 
circulatory system through proximal tubes in conjunction with glucose, sodium 
chloride, chloride, in addition water [<xref ref-type="bibr" rid="ref17">17</xref>], as shown in the Fig. <xref ref-type="fig" rid="F1">1</xref>, Ref. [<xref ref-type="bibr" rid="ref18">18</xref>]; 
Fig. <xref ref-type="fig" rid="F2">2</xref>, Ref. [<xref ref-type="bibr" rid="ref18">18</xref>].</p> 


<fig id="F1" orientation="portrait" position="float">
<label>Figure 1:</label>
<caption><p><bold>Location of a kidney stone in the urinary system [<xref ref-type="bibr" rid="ref18">18</xref>].</bold></p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jrenhep.com/article/download/210/version/183/363/2626/fig1.jpg"/>
</fig>


<fig id="F2" orientation="portrait" position="float">
<label>Figure 2:</label>
<caption><p><bold>Different types of kidney stones [<xref ref-type="bibr" rid="ref18">18</xref>].</bold></p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jrenhep.com/article/download/210/version/183/363/2627/fig2.jpg"/>
</fig>  
  
   </sec>  
   <sec id="S3">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Calcium stone contains calcium phosphate together with oxalate</title>  
     <p>Most urinary stones (around 80%) are calcium stones, which predominate among 
renal stones [<xref ref-type="bibr" rid="ref19">19</xref>]. 50 The majority of calcium stones consist of calcium oxalate 
(CaOx) as well as calcium phosphate (CaP), commonly referred to as apatite. Each 
factor individually accounts for 5 percent, and collectively they contribute 45 
percent [<xref ref-type="bibr" rid="ref20">20</xref>]. 
</p>  
   </sec>  
   <sec id="S4">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Struvite stones or magnesium ammonium phosphate rocks</title>  
     <p>These material stones, additionally referred to as infectious acute triple 
phosphate stones, are primarily linked to infection of the urinary tract produced 
by bacteria that generate urease, such as Proteus mirabilis, Klebsiella, among 
Pseudomonas. These microbes convert urea to ammonia, raising urine pH and aiding 
the precipitation of calcium, magnesium ammonium phosphate. Struvite stones may 
account for 10&#x2013;15% of all kidney-related stone cases, particularly in people 
who have frequent urinary tract infections (UTIs).</p>  
   </sec>  
   <sec id="S5">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Uric acid stone or urate</title>  
     <p>Urinary acid stones represent about 8&#x2013;10% of all renal calculi. They are 
commonly associated with conditions that cause increased purine metabolism, such 
as diets high in animal proteins (meat and fish), obesity, and gout. 
Hyperuricosuria (excess uric acid in urine) and persistently acidic urine (pH 
&lt;5.5) promote the crystallization producing uric acid, resulting in stone 
formation. Individuals with metabolic syndrome and chronic dehydration are also 
at elevated risk.</p>  
   </sec>  
   <sec id="S6">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Cystine stones</title>  
     <p>Below 2%, including all stone kinds are these stones. It is a hereditary 
condition that affects how an organic compound or cystine is transported. It 
causes an overabundance of cystinuria, an autosomal recessive disorder 
characterized by defective cystine tube absorption, especially cystine leakage 
into the urine, and is brought on by a genetic deficiency in the natural and 
basic amino acid transport protein gene located on a chromosome [<xref ref-type="bibr" rid="ref21">21</xref>]. It causes 
the production of cystine stones because it is not released in urine, as 
indicated in <xref ref-type="table" rid="T1">Table 1</xref> [<xref ref-type="bibr" rid="ref13">13</xref>, <xref ref-type="bibr" rid="ref14">14</xref>, <xref ref-type="bibr" rid="ref15">15</xref>].</p>  

<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Risk considerations for stone formation.</p></caption>
 
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">Disease</th> 
<th align="center">Threat factor</th></tr> 
</thead>
<tbody valign="top">
<tr> 
<td align="left">Hypercalcemic disorders</td> 
<td align="center">Primary hyperparathyroidism as well as other calcium metabolism issues.</td></tr> 
<tr> 
<td align="left">Recurrent urinary tract infections</td> 
<td align="center">Aberrant urine pH and urine that has been alkalinized by bacteria that produce urease, including Proteus mirabilis.</td></tr> 
<tr> 
<td align="left">Metabolic disorders</td> 
<td align="center">That includes a history of gout (a form of uric acid metabolism disorder), hypercalciuria, hypocitraturia, hyperoxaluria, as well as hyperuricosuria.</td></tr> 
</tbody> 
</table></table-wrap>  
   </sec>  
   <sec id="S7">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Pathophysiology of kidney stones</title>  
     <p>As per their chemical components, kidney stones are categorized. Many solutes 
inside the urine may crystallize, followed by lithogenesis [<xref ref-type="bibr" rid="ref22">22</xref>] (<xref ref-type="table" rid="T2">Table 2</xref>). Urine 
must have been supersaturated concerning the substance of the stone, which means 
the required concentration must be greater compared to the material&#x2019;s 
thermodynamic solubility, for crystal formation.</p>  

<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2.</label>
<caption>
<p>Main causes of calcium stone formation.</p></caption> 
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">Disease</th> 
<th align="center">Definitions</th> 
<th align="center">Etiology</th></tr> 
</thead>
<tbody valign="top">
<tr> 
<td align="left">Hypercalcinuria</td> 
<td align="center">Excessive urinary calcium excretion 200 mg/d</td> 
<td align="center">Absorbent hypercalcinuria: Enhance the urinary absorption of calcium in the digestive system.<br/> Hypercalcemia: Impairment of the kidneys, Resorptive.<br/> Hypercalciuria: Initial hyperparathyroidism.</td></tr> 
<tr> 
<td align="left">Hyperoxaluria</td> 
<td align="center">Excessive oxalate levels in urine 40 mg/d</td> 
<td align="center">First-stage hyperoxaluria: Genetics of oversupply of Oxalate and nutrients.<br/> Hyperoxaluria: Excess amount of food consumption causes.<br/> Entrance hyperoxaluria: Absorption of gastrointestinal oxalate.</td></tr> 
<tr> 
<td align="left">Hypocitraturia</td> 
<td align="center">Citrate is eliminated in the urine at a rate of 320 mg per day, significantly less</td> 
<td align="center">Distal tubular hyperkalemia: Reduced acidic expels from the renal tubules.<br/> Chronic diarrhea syndrome: Associated with gastrointestinal (GI) enzyme deficiency.<br/> Thiazide-induced: Hypokalaemia.</td></tr> 
<tr> 
<td align="left">Hyperuricosuria</td> 
<td align="center">High uric acid levels in the urine, 600 mg/d</td> 
<td align="center">Increased uric acid synthesis, dietary excretion, and urine production.</td></tr> 
</tbody> 
</table></table-wrap>  
   </sec>  
   <sec id="S8">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Pathogenesis and mechanism of kidney stone formation</title>  
     <p>Urine must release crystalloids that can form stones for renal stones to 
develop. With calcium oxalate and phosphate combined, calcium serves as the 
primary constituent of more than 75 percent of all gravels. Several stages, like 
calcium oxalate (CaOx) or calcium phosphate build-up, occur during calcium stones 
(CAP) production [<xref ref-type="bibr" rid="ref23">23</xref>], as shown in the Fig. <xref ref-type="fig" rid="F3">3</xref> (Ref. [<xref ref-type="bibr" rid="ref24">24</xref>]).</p>  
     
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3:</label>
<caption><p><bold>An illustration showing how calcium oxalate kidney stone 
development is induced and inhibited [<xref ref-type="bibr" rid="ref24">24</xref>].</bold></p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jrenhep.com/article/download/210/version/183/363/2628/fig3.jpg"/>
</fig>	 
	
	 
     <p>This procedure is encouraging the production of stones.</p>  
     <p>&#x2022; Urinary supersaturation.</p>  
     <p>&#x2022; Crystals nucleation.</p>  
     <p>&#x2022; Crystals accumulation.</p>  
     <p>&#x2022; Crystals retain.</p>  
     <sec id="S8_1">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Urinary supersaturation and crystallization</title>  
       <p>The cause of crystal growth in the kidneys is urinary supersaturation. 
Supersaturation is unquestionably necessary for stone synthesis since it&#x2019;s 
important for the initiation of the development of crystalline particles [<xref ref-type="bibr" rid="ref25">25</xref>].</p>  
     </sec>  
     <sec id="S8_2">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Crystal nucleation</title>  
       <p>When a supersaturated solution changes from a state of fluid to a solid phase, 
the process is referred to as nucleation [<xref ref-type="bibr" rid="ref26">26</xref>].</p>  
     </sec>  
     <sec id="S8_3">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Crystals developing</title>  
       <p>After the crystal&#x2019;s nucleus approaches an appropriate dimension and comparative 
excessive saturation has passed, adding more crystal components causes the total 
free energy to decrease [<xref ref-type="bibr" rid="ref27">27</xref>].</p>  
     </sec>  
     <sec id="S8_4">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Crystals accumulation</title>  
       <p>When minerals in the resolution work together to produce bigger particles, the 
process is termed agglomeration. According to several studies, crystal gathering 
is the critical stage in the production of stones. Although crystal development 
is undoubtedly a phase in the creation of CaOx renal stone, crystals develop at a 
sluggish rate.</p>  
     </sec>  
   </sec>  
   <sec id="S9">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Integrated approaches for the management of kidney stones: 
pharmacological and non-pharmacological strategies</title>  
     <p>The management of kidney stones encompasses a comprehensive spectrum of 
pharmacological and non-pharmacological interventions aimed at both treating 
existing calculi and preventing recurrence Fig. <xref ref-type="fig" rid="F4">4</xref> (Ref. [<xref ref-type="bibr" rid="ref28">28</xref>]). Pharmacological 
treatments primarily focus on modifying the biochemical environment of the urine 
to inhibit stone formation or aid in stone dissolution. Agents such as thiazide 
diuretics are commonly used to reduce urinary calcium excretion in patients with 
calcium-containing stones, while potassium citrate is frequently administered to 
alkalinize urine and prevent the crystallization of uric acid and cystine stones. 
Allopurinol, a xanthine oxidase inhibitor, is prescribed in hyperuricosuric 
patients to lower uric acid levels. Additionally, magnesium supplements and 
phosphate salts may be used to stabilize urinary constituents and prevent stone 
aggregation [<xref ref-type="bibr" rid="ref29">29</xref>].</p>  
     
<fig id="F4" orientation="portrait" position="float">
<label>Figure 4:</label>
<caption><p><bold>Overview of pharmacological and non-pharmacological strategies 
for the management of kidney stones [<xref ref-type="bibr" rid="ref28">28</xref>].</bold></p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jrenhep.com/article/download/210/version/183/363/2629/fig4.jpg"/>
</fig>	 
	 
     <p>On the other hand, non-pharmacological strategies play a vital role in long-term 
stone prevention and include dietary modifications, adequate hydration, and 
lifestyle adjustments. Increasing fluid intake to maintain a urine output of at 
least 2 to 2.5 liters per day is a foundational recommendation, as it dilutes 
urinary solutes and reduces supersaturation. Dietary interventions emphasize 
reducing the intake of oxalate-rich foods, sodium, and animal proteins while 
ensuring adequate calcium intake from dietary sources to bind oxalates in the 
gut. Lifestyle modifications such as maintaining a healthy body weight and 
engaging in regular physical activity have also been associated with reduced 
stone risk [<xref ref-type="bibr" rid="ref30">30</xref>]. Together, these integrative approaches underscore the importance 
of individualized, patient-centered management plans that address both the 
biochemical and behavioral aspects of kidney stone disease, thereby improving 
clinical outcomes and minimizing recurrence rates.</p>  
     <sec id="S9_1">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Pharmacological treatment of kidney stones</title>  
       <p>Urine production should be at least 1/2 day; therefore, intake of fluids should 
be enough. Patients with moderate-to-severe stone disease should be the only ones 
who take medications. There is the various pharmacological treatments for kidney 
stones.</p>  
       <sec id="S9_1_1">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Hypercalciuria</title>  
         <p>Hypercalciuric nephrolithiasis has frequently been treated with hypocalciuric 
action. These drugs are specifically approved for treating renal hypercalciuria 
because they target the urinary tract, where they directly increase calcium 
reabsorption in the renal tubules. However, they are also often used in 
absorptive hypercalciuria with acceptable management of hypercalciuria [<xref ref-type="bibr" rid="ref31">31</xref>].</p>  
       </sec>  
       <sec id="S9_1_2">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Indapamide</title>  
         <p>Although it has the capability to treat hypercalciuria, indapamide can also 
cause hypokalaemia and hypocitraturia. It can be administered once daily (2.5 
mg/day) as a long-acting diuretic. For the best hypercalciuria management with 
hypocalciuric medicines, sodium intake from food should be limited to a lower 
than 100 mEq/day. Over potassium chloride, potassium citrate is recommended [<xref ref-type="bibr" rid="ref32">32</xref>]. 
</p>  
       </sec>  
       <sec id="S9_1_3">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Hypocitraturia</title>  
         <p>Hypocitraturia (150 mg/day) typically denotes conditions characterized by a 
significant level of acid or acidic conditions, such as proximal renal tubular 
acidosis, persistent diarrhea, severe exercise, or topiramate medication.</p>  
       </sec>  
       <sec id="S9_1_4">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Hyperoxaluria</title>  
         <p>The limitation of dietary oxalate and an increase in fluid consumption are 
essential. Potassium citrate might be used for the treatment of associated 
hypocitraturia and low urine pH in chronic diarrheal conditions accompanied by 
moderate-severe hyperoxaluria [<xref ref-type="bibr" rid="ref33">33</xref>].</p>  
         <p>Calcium citrate (500 mg calcium bi-daily) may treat calcium shortage and reduce 
urinary oxalate when urine calcium levels are low [<xref ref-type="bibr" rid="ref34">34</xref>].</p>  
       </sec>  
       <sec id="S9_1_5">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Hyperuricosuria</title>  
         <p>Allopurinol may be recommended for severe hyperuricosuria (&gt;850 mg/day) or to 
coexist with hyperuricemia.</p>  
       </sec>  
       <sec id="S9_1_6">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Allopurinol</title>  
         <p>By deactivating xanthine oxidase, this substance suppresses the transformation 
of xanthine into uric acid. In the majority of people who develop stones, each 
day, 300 mg of allopurinol can be taken to obtain appropriate treatment for 
hyperuricemia or hyperuricosuria [<xref ref-type="bibr" rid="ref35">35</xref>, <xref ref-type="bibr" rid="ref36">36</xref>, <xref ref-type="bibr" rid="ref37">37</xref>] (<xref ref-type="table" rid="T3">Table 3</xref>, Ref. [<xref ref-type="bibr" rid="ref38">38</xref>, <xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref40">40</xref>, <xref ref-type="bibr" rid="ref41">41</xref>, <xref ref-type="bibr" rid="ref42">42</xref>]).</p>  

<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3.</label>
<caption>
<p>Kidney stones and their effect or treatment in human studies.</p></caption>
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">No.</th> 
<th align="center">Study Author</th> 
<th align="center">Treatment</th> 
<th align="center">Effect</th> 
<th align="center">Result</th></tr> 
</thead>
<tbody valign="top">
<tr> 
<td align="left">1</td> 
<td align="center">Malihi Z <italic>et al</italic>. [<xref ref-type="bibr" rid="ref38">38</xref>] 2020</td> 
<td align="center">Hypercalciuria</td> 
<td align="center">Patients with hypercalciuria are more likely to experience osteoporosis-causing bone loss.</td> 
<td align="center">The baseline dose and duration of 25-hydroxyvitamin D co-supplementation did not affect the relationship between vitamin D intake and the risk of either hypercalciuria causing kidney stone development.</td></tr> 
<tr> 
<td align="left">3</td> 
<td align="center">Ceylan K <italic>et al</italic>. [<xref ref-type="bibr" rid="ref39">39</xref>] 2016</td> 
<td align="center">Indapamide</td> 
<td align="center">In individuals with high urine calcium concentrations, it is efficient and advised for the prevention of recurring calcium stones.</td> 
<td align="center">Median parathyroid hormone, potassium levels, and diastolic and systolic blood pressure measurements were all significantly lower than expected. Serum uric acid and levels of triglycerides were significantly elevated.</td></tr> 
<tr> 
<td align="left">4</td> 
<td align="center">Shabani Nashtaei M <italic>et al</italic>. [<xref ref-type="bibr" rid="ref40">40</xref>] 2019</td> 
<td align="center">Hyperoxaluria</td> 
<td align="center">When a person has hyperoxaluria, their urine contains excessive amounts of oxalate, a substance that can cause kidney stones.</td> 
<td align="center">Researchers demonstrated that the existence of O. formigenes might decrease the development of 24-hour urine oxalate and its function in hyperoxaluria, although it may not necessarily be caused by kidney stone illness.</td></tr> 
<tr> 
<td align="left">5</td> 
<td align="center">Spivacow FR <italic>et al</italic>. [<xref ref-type="bibr" rid="ref41">41</xref>] 2016</td> 
<td align="center">Hyperuricosuria</td> 
<td align="center">Rising uric acid output in the urine and calcium stone illness.</td> 
<td align="center">When untreated and even after uric acid production has been reduced with a xanthine dehydrogenase inhibitor like allopurinol, hyperuricosuria frequently causes the development of stones in the nephrocalyceal medullae, or known as the urological system.</td></tr> 
<tr> 
<td align="left">6</td> 
<td align="center">Astroza GM <italic>et al</italic>. [<xref ref-type="bibr" rid="ref42">42</xref>] 2016</td> 
<td align="center">Hypocitraturia</td> 
<td align="center">Citrate prevents the formation of stones by preventing the nucleation, proliferation, and crystallization of calcium in the urine.</td> 
<td align="center">Between 20% and 60% of the stones in the kidney form have hypocitraturia, a common metabolic disorder.<br/> It denotes a low concentration of the acid in the urine.</td></tr> 
</tbody> 
</table></table-wrap>  
       </sec>  
       <sec id="S9_1_7">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>Potassium citrate</title>  
         <p>The addition of potassium citrate could be an option for people who have a rise 
in urine uric acid of mild to moderate severity (600&#x2013;850 mg/day) or who have 
allopurinol adverse effects <xref ref-type="table" rid="T4">Table 4</xref> [<xref ref-type="bibr" rid="ref36">36</xref>].</p>  

<table-wrap id="T4" orientation="portrait" position="float">
<label>Table 4.</label>
<caption>
<p>Pathophysiological conditions and mechanisms of kidney stone 
formation.</p></caption>
<table frame="border" rules="all">
<thead valign="top">
<tr> 
<th align="left">Condition</th> 
<th align="center">Drug</th> 
<th align="center">Dose</th> 
<th align="center">MOA</th></tr> 
</thead>
<tbody valign="top">
<tr> 
<td align="left">Renal hypercalciuria</td> 
<td align="center">Indapamide</td> 
<td align="center">4 mg</td> 
<td align="center">&#x2191; Reabsorption of renal calcium</td></tr> 
<tr> 
<td align="left">Hypocitraturia</td> 
<td align="center">Potassium Citrate</td> 
<td align="center">20 mg</td> 
<td align="center">&#x2191; Urinary citrate<br/> &#x2193; Urinary calcium</td></tr> 
<tr> 
<td align="left">Hyperoxaluria</td> 
<td align="center">Potassium Citrate</td> 
<td align="center">20 mg</td> 
<td align="center">&#x2191; Urinary citrate<br/> &#x2193; Urinary oxalate</td></tr> 
<tr> 
<td align="left">Hyperuricosuria</td> 
<td align="center">Allopurinol</td> 
<td align="center">20&#x2013;30 mg</td> 
<td align="center">&#x2193; Serum and urinary uric acid</td></tr> 
</tbody>
</table>
<table-wrap-foot>
<fn id="TF1-1"><p>MOA: Mechanism of action. &#x2191; indicates increase; &#x2193; indicates decrease.</p></fn></table-wrap-foot>
</table-wrap>  
       </sec>  
     </sec>  
     <sec id="S9_2">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Non-pharmacological treatment of kidney stones</title>  
       <sec id="S9_2_1">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Asparagus racemosus</italic>  
         </title>  
         <p>The plant <italic>Asparagus racemosus</italic>, also referred to as Shatavari or 
shatamuli, is a member of the Asparagaceae family. The roots of the plant, dried, 
exhibited galactagogue, antitussive, antibacterial in nature, antisecretory, 
anti-ulcer, anti-protozoal, anti-hepatotoxic, antioxidants, antineoplastic, 
adaptogenic, antilithiatic activities, among other properties [<xref ref-type="bibr" rid="ref42">42</xref>].</p>  
       </sec>  
       <sec id="S9_2_2">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Viratarvadigane</italic>  
         </title>  
         <p>The Amaranthaceae family includes <italic>Viratarvadigana</italic>, also known as 
Celosia argentea. The leaves and stems of the plant are used to cure urinary 
problems, eye problems, diarrhea, and sore mouth [<xref ref-type="bibr" rid="ref43">43</xref>].</p>  
       </sec>  
       <sec id="S9_2_3">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Boerhaavia diffusa</italic>  
         </title>  
         <p>The Nyctaginaceae family includes <italic>Boerhaavia diffusa</italic>, which is 
additionally known as <italic>Punarnava</italic> herb, <italic>Santhi</italic>, 
<italic>Sanadika</italic>, <italic>Gonajali</italic>, <italic>Sanadika</italic>, <italic>Sothaghna</italic>, and 
other names. Punarnava serves as a kidney treatment and assists in the 
expulsion of kidney stones; hence, it is advised for those with renal and urinary 
illnesses [<xref ref-type="bibr" rid="ref44">44</xref>].</p>  
       </sec>  
       <sec id="S9_2_4">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Tribulus terrestris</italic>  
         </title>  
         <p>A member of the Zygophyllaceae family, <italic>Tribulus Terrestris</italic> is commonly 
referred to as Gokshura or Tribulus. Roots and fruits of <italic>Tribulus 
Terrestris</italic> help treat stones in the kidneys, impotence, and painful urinary 
tract infections [<xref ref-type="bibr" rid="ref45">45</xref>].</p>  
       </sec>  
       <sec id="S9_2_5">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Phyllanthus niuri</italic>  
         </title>  
         <p>The plant <italic>Phyllanthus niruri</italic>, often called Chanca piedra or 
stonebreaker, is a member of the Euphorbiaceae family. <italic>Phyllanthus 
niruri</italic> compounds act against fungi, bacteria, inflammation, hyperglycemia, 
analgesia, hepatoprotection, and lithiasis [<xref ref-type="bibr" rid="ref46">46</xref>].</p>  
       </sec>  
       <sec id="S9_2_6">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Ammi visnaga</italic>  
         </title>  
         <p>A member of the Apiaceae family is <italic>Ammi Visnaga</italic>, also known as Khella. 
People with kidney stones have traditionally used a variety of teas brewed from 
the vegetables and fruits of A. visnaga [<xref ref-type="bibr" rid="ref47">47</xref>].</p>  
       </sec>  
       <sec id="S9_2_7">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Crataeva nurvula</italic>  
         </title>  
         <p>A member of the Capparidaceae family, <italic>Crataeva nurvala</italic> is commonly 
referred to as Varuna bark and Varuna. According to research, the main ingredient 
in C. nurvala, lupeol, inhibits the enzyme glycolate oxidase, reducing the body&#x2019;s 
production of oxalates [<xref ref-type="bibr" rid="ref48">48</xref>].</p>  
       </sec>  
       <sec id="S9_2_8">  
         <!-- The element tags   
is currently not supported for the main body. 
	-->  
         <title>  
           <italic>Oenothera biennis</italic>  
         </title>  
         <p>The plant <italic>Oenothera biennis</italic>, sometimes known as evening primrose, is a 
member of the Onagraceae family. By suppressing lipogenesis and increasing the 
level of citrate in the urine while lowering oxalate concentration in urine by 
changing the membrane fatty acids, daily use of primrose in the evening renal 
stones by lowering risk by 1000 mg/day of seed oil intake [<xref ref-type="bibr" rid="ref49">49</xref>].</p>  
       </sec>  
     </sec>  
   </sec>  
   <sec id="S10">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Prevention of kidney stones</title>  
     <p>A low-cost public health project with significant social repercussions is the 
primary prevention of the formation of stones in their kidneys by diet 
modification.</p>  
     <p>The greatest way to avoid urolithiasis is through dietary control [<xref ref-type="bibr" rid="ref50">50</xref>]. Patients 
should be told to drink more water so they can keep their urine production at 
least 2 liters each day. Drinking more water or other liquids is the easiest and 
most crucial change you can make to your lifestyle to prevent stone illness [<xref ref-type="bibr" rid="ref51">51</xref>] 
(<xref ref-type="table" rid="T5">Table 5</xref>, Ref. [<xref ref-type="bibr" rid="ref52">52</xref>, <xref ref-type="bibr" rid="ref53">53</xref>, <xref ref-type="bibr" rid="ref54">54</xref>, <xref ref-type="bibr" rid="ref55">55</xref>, <xref ref-type="bibr" rid="ref56">56</xref>, <xref ref-type="bibr" rid="ref57">57</xref>, <xref ref-type="bibr" rid="ref58">58</xref>]).</p>  

<table-wrap id="T5" orientation="portrait" position="float">
<label>Table 5.</label>
<caption>
<p>Clinical trial.</p></caption> 
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">Clinical Trial</th> 
<th align="center">Title</th> 
<th align="center">Condition</th> 
<th align="center">Phase</th> 
<th align="center">Treatment</th> 
<th align="center">References</th></tr> 
</thead>
<tbody valign="top">
<tr> 
<td align="left">NCT02645058</td> 
<td align="center">RIRS Against ESWL for Treatment of Renal Stones</td> 
<td align="center">Kidney Stone</td> 
<td align="center">Not Applicable</td> 
<td align="center">RIRS (Retrograde intrarenal surgery)</td> 
<td align="center">[<xref ref-type="bibr" rid="ref52">52</xref>]</td></tr> 
<tr> 
<td align="left">NCT05855057</td> 
<td align="center">Efficacy of US-Guided PCNL surrounding Diverse Positions for Renal Stone Treatment</td> 
<td align="center">Kidney Stone</td> 
<td align="center">Phase 1</td> 
<td align="center">Flank suspended supine position percutaneous nephrolithotomy</td> 
<td align="center">[<xref ref-type="bibr" rid="ref53">53</xref>]</td></tr> 
<tr> 
<td align="left">NCT02090439</td> 
<td align="center">Silodosin&#x2019;s effectiveness when utilised as expulsive therapies for ureteral pelvic stones</td> 
<td align="center">Kidney stone</td> 
<td align="center">Phase 3</td> 
<td align="center">Drug: Silodosin</td> 
<td align="center">[<xref ref-type="bibr" rid="ref54">54</xref>]</td></tr> 
<tr> 
<td align="left">NCT02373384</td> 
<td align="center">Predictors of Successful Oral Dissolution Therapy with Radiolucent Renal Stones</td> 
<td align="center">Kidney stone</td> 
<td align="center">Phase 4</td> 
<td align="center">Drug: Oral alkalinization (Potassium citrate, Allopurinol)</td> 
<td align="center">[<xref ref-type="bibr" rid="ref55">55</xref>]</td></tr> 
<tr> 
<td align="left">NCT02404701</td> 
<td align="center">Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk</td> 
<td align="center">Kidney stone</td> 
<td align="center">Not Applicable</td> 
<td align="center">Dietary Supplement: Aloe vera with Cranberry</td> 
<td align="center">[<xref ref-type="bibr" rid="ref56">56</xref>]</td></tr> 
<tr> 
<td align="left">NCT03567421</td> 
<td align="center">Ureteral Stenting Following Ureteroscopy with Stone Treatment options: A Worldwide View on Indications and Results</td> 
<td align="center">Kidney Stone</td> 
<td align="center">Phase 2</td> 
<td align="center">RIRS (Retrograde intrarenal surgery)</td> 
<td align="center">[<xref ref-type="bibr" rid="ref57">57</xref>]</td></tr> 
<tr> 
<td align="left">NCT01022060</td> 
<td align="center">Renal Development and Dissolution of Renal Calculi within Patients alongside Recurrent Calcic Lithiasis</td> 
<td align="center">Kidney Stone</td> 
<td align="center">Phase 3</td> 
<td align="center">Dietary Supplement: Renalo, Placebo</td> 
<td align="center">[<xref ref-type="bibr" rid="ref58">58</xref>]</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TF1-1"><p>ESWL: Extracorporeal Shock Wave Lithotripsy; US: United States; PCNL: 
Percutaneous nephrolithotomy.</p></fn></table-wrap-foot> 
</table-wrap>  
   </sec>  
   <sec id="S11">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Nutritional aspects of nephrolithiasis</title>  
     <p>The natural progression of stone diseases among children is less well understood 
than that in adults [<xref ref-type="bibr" rid="ref59">59</xref>]. The condition is associated with significant morbidity, 
including confirmed instances of recurrence fluctuating between 6.5 to 44% [<xref ref-type="bibr" rid="ref60">60</xref>]. 
Barring follow-up along with medical intervention, the recurrence probability can 
approach 50% after 5&#x2013;6 years. Nephrolithiasis can result in a variety of urine 
composition concerns.</p>  
     <p>Urinary abnormalities might be induced by dietary, physiological, or metabolic 
alterations. Reducing abnormal risk factors through dietary and pharmacological 
therapies can help avoid repeated stone formation [<xref ref-type="bibr" rid="ref61">61</xref>]. Urolithiasis epidemiology 
varies according to location and history.</p>  
     <p>Vesical stones in children are still a problem in developing countries. Calculi 
based on ammonium urate as well as calcium oxalate are widely distributed in 
&#x201C;primitive&#x201D; vesical stones across Asia [<xref ref-type="bibr" rid="ref62">62</xref>]. Malnutrition during childhood is a 
prominent cause of vesical stones in Turkey, Iran, India, China, Indochina, as 
well as Indonesia.</p>  
     <p>However, a decline in prevalence is often observed in conjunction with enhanced 
socioeconomic conditions.</p>  
     <p>India, Pakistan, and especially Southern China make up a substantial portion 
underlying Asia&#x2019;s stone belt. Calcium oxalate causes 45&#x2013;65% of all children&#x2019;s 
gemstones, followed by calcium phosphate (14&#x2013;30%), struvite (13%), cystine 
(5%), uric acid (45%), and lastly mixed as well as miscellaneous <xref ref-type="table" rid="T6">Table 6</xref> [<xref ref-type="bibr" rid="ref63">63</xref>].</p>  

<table-wrap id="T6" orientation="portrait" position="float">
<label>Table 6.</label>
<caption>
<p>Dietary factors can influence both oxalate and calcium stone 
development.</p></caption>
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">Dietary factors</th> 
<th align="center">Proposed mechanism(s)</th></tr> 
</thead> 
<tbody valign="top">
<tr> 
<td align="left">Oxalate</td> 
<td align="center">Excess oxalate excretion in urine</td></tr> 
<tr> 
<td align="left">Sodium</td> 
<td align="center">Increased urinary calcium excretion</td></tr> 
<tr> 
<td align="left">Animal protein</td> 
<td align="center">Calcium and uric acid excretion increased, but citrate extraction was reduced in the urine</td></tr> 
<tr> 
<td align="left">Vitamin C</td> 
<td align="center">Higher oxalate synthesis and excretion</td></tr> 
<tr> 
<td align="left">Carbohydrates Decreased risk</td> 
<td align="center">Increased urinary calcium excretion</td></tr> 
<tr> 
<td align="left">Dietary calcium Potassium</td> 
<td align="center">Urinary citrate excretion rose, whereas calcium excretion declined</td></tr> 
<tr> 
<td align="left">Phytate</td> 
<td align="center">Calcium oxalate absorption and crystallization are inhibited</td></tr> 
<tr> 
<td align="left">Magnesium</td> 
<td align="center">Vitamin B6 deficiency can enhance the development of oxalate and cause oxaluria</td></tr> 
</tbody> 
</table></table-wrap>  
     <p>In the 1970s, a high-protein, refined carbohydrate, and salt diet was discovered 
as a risk factors for oxalate of calcium stones. Nevertheless, the significance 
of dietary calcium and oxalate remains unknown.</p>  
     <p>Calcium stone formation may be genetically determined [<xref ref-type="bibr" rid="ref64">64</xref>].</p>  
     <p>Although family history is highly associated with idiopathic calcium stone 
disease, little is known regarding metabolic changes that contribute to this 
vulnerability and hereditary communication.</p>  
   </sec>  
   <sec id="S12">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Nutrition for children and kidney stones</title>  
     <p>Idiopathic hypercalciuria in children is commonly treated with dietary or 
pharmacological measures [<xref ref-type="bibr" rid="ref65">65</xref>]. The long-term impact of hypercalcemia on broods is 
unknown. Urinary stones are classified into two types: bladder stones in children 
(which departed from Europe towards the end nineteenth and early twentieth 
century), adults with upper urinary tract stones [<xref ref-type="bibr" rid="ref66">66</xref>].</p>  
     <p>Improved nutrition has helped to reduce the incidence of endemic bladder stones 
in various nations along the belt. Stone formation is mostly determined by urine 
composition, which reflects food trends in the individual countries. A diet low 
in overall animal protein, calcium, magnesium phosphorus yet rich in acidogenic 
grains is the leading cause of bladder stones in children [<xref ref-type="bibr" rid="ref67">67</xref>].</p>  
     <p>In Thailand, endemic areas have reported early weaning using Pre-masticated 
rice, veggies, along with undercooked fermented fish as the primary source of 
animal protein. Vesical stones are more prevalent in places with mild to average 
protein-energy deficit (PEM) compared to those with severe PEM.</p>  
     <p>In a retrospective study of 1440 idiopathic stone patients in Pakistan, 
hypercalciuria was detected in 11%, hyperoxaluria 40%, hyperuricosuria in 27%, 
and hypocitruria in 63%. Consumption of protein was low in 60 individuals 
(44%), calcium in 45 (33%), potassium in 105 (77%), alongside oxalate in 75 
(55%). The lumps were composed of either calcium oxalate (47%), ammonium 
hydrogen urate (27%), or struvite (6.4%) [<xref ref-type="bibr" rid="ref68">68</xref>].</p>  
     <p>Children without urolithiasis frequently have a lower 24-hour quantity of urine 
than other children. In the year a study of 32 kids diagnosed with urolithiasis, 
urine flow greater than 1 mL/kg/h significantly reduced the likelihood of calcium 
oxalate, calcium phosphate, especially uric acid supersaturation, hence 
preventing kidney stones.</p>  
     <p>For a youngster measuring 40 kg, this corresponds to 960 cc of pee every day.</p>  
     <p>Patients with cystinuria may require higher urine flow, but primary xanthinuria 
may necessitate significant fluid intake [<xref ref-type="bibr" rid="ref69">69</xref>]. These people should consume enough 
milk to satisfy their calcium and protein requirements.</p>  
     <p>Although excessive fluid consumption has had minimal success in children, it is 
nevertheless suggested to raise urine volume according to body size. Therapeutic 
medicines that increase urine citrate concentration may assist children with 
hypocitraturia. Children with residual stone fragments should be advised to 
maintain high fluid intake and use potassium citrate to reduce the risk of 
recurrent stone formation [<xref ref-type="bibr" rid="ref70">70</xref>]. 
</p>  
   </sec>  
   <sec id="S13">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Nutritional factors for nephrolithiasis</title>  
     <sec id="S13_1">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Water and other fluids</title>  
       <p>According to research, those who consume less than 1.5 L of fluids per day have 
a 50% higher chance of acquiring kidney stones than those who consume more than 
2.5 L.</p>  
       <p>Two studies, one observational and one interventional, suggest that drinking 
plenty of water helps prevent kidney disease and lessen recurrence [<xref ref-type="bibr" rid="ref71">71</xref>]. After a 
5-year follow-up, the subsequent recurrence rate decreased by 27% reduced 12% 
and daily water intake rose from 1 to 2 L.</p>  
       <p>Although water is essential for avoiding nephrolithiasis, it is unknown if hard 
water with high divalent ion levels contains the same anti-lithogenic properties 
as fresh water and leaves little dry residue. Consider trace elements, including 
calcium, sodium, potassium, chloride, magnesium, iron, fluorine, iodine, zinc, 
among selenium when determining how much water you consume [<xref ref-type="bibr" rid="ref72">72</xref>]. However, 
adopting oligomineral, low NaCl (sodium chloride) water appears to be a viable solution.</p>  
       <p>Drinks that boost pH, Citric acid along with volume, which includes freshly 
squeezed oranges with lemons, juices, green tea, and wine, can be a good 
substitute for water.</p>  
       <p>Beer prevents calcium stone disease but raises the hazard of urate stone disease 
due to its high purine-guanosine satisfied [<xref ref-type="bibr" rid="ref73">73</xref>]. Cranberry juice may not prevent 
calcium nephrolithiasis, but it can help cure infected stones.</p>  
       <p>Tea and coffee enhance oxalate levels; however, adding milk can decrease this 
effect because calcium binds to oxalate and limits absorption. Some drinks, 
including grapefruit and apple juice, as well as cola, may stimulate lithogenesis 
through an unknown mechanism [<xref ref-type="bibr" rid="ref74">74</xref>].</p>  
     </sec>  
     <sec id="S13_2">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Fluid intake</title>  
       <p>Low amount of urine, resulting from inadequate one of the most significant risk 
factors underlying kidney stone formation is excessive fluid consumption as well 
as loss. Many pharmacological and pathophysiological disorders can cause 
dehydration, which alters water requirements [<xref ref-type="bibr" rid="ref75">75</xref>]. These causes include excessive 
perspiration as a result of temperature exposure, mental stress, and intense 
workout levels, and profession, as well as persistent diarrhoea as a result of 
fat malabsorption caused by various gastrointestinal illnesses.</p>  
       <p>An investigation of 100 steel manufacturing employees discovered that 16% 
exhibited a history of stone disease, and more exceeding half had urine 
osmolality levels more than 700 mOsm, suggesting dehydration. Health care workers 
who have limited access to potable water are furthermore at a higher risk of 
acquiring stones. A survey of workers revealed that physicians who worked in an 
operating theatre had the highest occurrence of nephrolithiasis (17.4% compared 
9.7%), as well as higher stress levels, in addition to lower fluid consumption 
compared to workers working elsewhere [<xref ref-type="bibr" rid="ref76">76</xref>]. Other occupations that can contribute 
to urolithiasis include professional drivers, aeroplane pilots, and 
schoolteachers.</p>  
     </sec>  
     <sec id="S13_3">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Tap and mineral water</title>  
       <p>The effect of tap versus mineral water concentrations on kidney stone formation 
is still debated. The composition of drinking water, notably the percentage of 
divalent cations including magnesium and calcium, varies substantially among 
geographic regions within the same country.</p>  
       <p>Hard tap water with a calcium carbonate level of more than 120 mg/L can 
contribute to the daily consumption of calcium. A study of 2295 individuals from 
two sites in the United States found that those who consume water from the faucet 
from a private well are more likely to acquire urinary stones. However, the cause 
of the higher risk among individual well users remains unknown. Numerous cohort 
studies demonstrated no relationship between the level of hardness of public 
water supply and urinary disease associated with stones [<xref ref-type="bibr" rid="ref77">77</xref>].</p>  
       <p>Bicarbonate, like calcium, magnesium, and other ions, is a reasonable component 
of inorganic water, as opposed to tap water. Bicarbonate enhances the body&#x2019;s 
buffering capacity and acts as a powerful alkalising agent. Water from minerals 
rich in bicarbonate might aid in alkalinisation treatment and contribute to 
urinary inhibitory potential by raising urinary pH affects citrate excretion. 
Another randomised crossover trial with healthy participants looked at how an 
equimolar acidic load, either a form of bicarbonate-rich mineral water or 
potassium citrate, affected the urinary risk profile towards calcium oxalate as 
well as uric acid stone development.</p>  
       <p>Consuming 2 L/day of mineral-enriched water with 1715 mg/L bicarbonate, either 
2.55 g/day potassium citrate significantly increased urinary pH along with 
citrate excretion while decreased oxalate excretion [<xref ref-type="bibr" rid="ref78">78</xref>].</p>  
       <p>Both categories had a significant reduction in the relative overabundance of 
calcium oxalate as well as uric acid. A study of healthy persons conducted under 
controlled dietary conditions discovered that consuming mineral water rich in 
bicarbonate, calcium, plus magnesium increased urine pH as well as the excretion 
of citrate and magnesium, which are urinary inhibitors against calcium oxalate 
stone formation. Calcium excretion rose considerably, although the corresponding 
supersaturation associated with calcium oxalate remained the same [<xref ref-type="bibr" rid="ref79">79</xref>].</p>  
     </sec>  
     <sec id="S13_4">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Fruit juices as well as juice-based drinks</title>  
       <p>The impact of fruit juices on metabolism is largely influenced by their alkali 
citrate content. When consumed, dietary citrate is absorbed in the digestive 
system and transformed into bicarbonate, which can raise both urine pH and the 
amount of citrate excreted. Citrus juices like lemon, orange, and grapefruit are 
rich sources of citric acid and can serve as natural alternatives to medicinal 
alkalizing agents [<xref ref-type="bibr" rid="ref80">80</xref>]. Among these, orange juice is one of the most commonly 
consumed worldwide. However, studies on how orange juice affects urine factors 
linked to kidney stone formation have shown mixed results.</p>  
       <p>Some large-scale cohort studies suggest that regularly drinking orange juice may 
lower the risk of developing kidney stones. Controlled trials under specific 
dietary conditions have shown that orange juice provides an alkaline effect, 
leading to higher urine pH and citrate output. Still, despite this alkalizing 
benefit, most studies found that orange juice did not significantly reduce the 
risk of forming calcium oxalate stones [<xref ref-type="bibr" rid="ref81">81</xref>]. Although orange juice has a low 
oxalate content, two out of three studies reported a noticeable rise in urinary 
oxalate levels, possibly due to the conversion of vitamin C (ascorbic acid) into 
oxalate inside the body.</p>  
       <p>Because of concerns about the high sugar and calorie content of orange juice and 
its low fiber, health experts often recommend eating whole fruits instead. It&#x2019;s 
advised to limit fruit juice to one serving a day and to dilute it with water 
when consumed [<xref ref-type="bibr" rid="ref82">82</xref>]. In a small crossover trial involving 10 healthy individuals 
on a regular diet, researchers compared Crystal Light lemonade with two 
reduced-calorie orange juice drinks. They found that only the Kroger brand 
low-calorie orange juice had a notable effect, though changes in citrate levels, 
an important factor in preventing calcium oxalate stones, were not significantly 
different between the beverages [<xref ref-type="bibr" rid="ref83">83</xref>].</p>  
       <p>Additionally, potential health risks from excessive juice consumption and 
concerns about additives like artificial colors, preservatives, sweeteners, and 
ingredients such as added ascorbic acid and calcium limit the suitability of 
these drinks for individuals prone to kidney stones.</p>  
     </sec>  
     <sec id="S13_5">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Soft drinks</title>  
       <p>In a large randomized controlled trial involving individuals who regularly 
consumed soft drinks (at least 160 mL per day), male participants were randomly 
assigned to either stop drinking soft drinks or continue their usual intake as 
part of the control group. The results showed that soft drink consumption, 
especially beverages containing phosphoric acid, was associated with a higher 
risk of repeated kidney stone formation [<xref ref-type="bibr" rid="ref84">84</xref>].</p>  
       <p>Further evidence from large-scale studies, including the Health Professionals 
Follow-Up Study (HPFS) and Nurses&#x2019; Health Studies (NHS I and II), which tracked 
194,095 participants over more than eight years, also found a strong link between 
the intake of sugar-sweetened cola and non-cola soft drinks and an increased risk 
of kidney stones.</p>  
       <p>Additionally, a cross-sectional analysis based on the Third National Health and 
Nutrition Examination Survey (NHANES-III) showed that people who consumed more 
sugar-sweetened soft drinks had higher levels of uric acid in their blood and 
were more likely to suffer from hyperuricemia. Long-term cohort studies have 
further supported this association, identifying a clear connection between sugary 
soft drink intake and a higher risk of developing gout, particularly in men [<xref ref-type="bibr" rid="ref85">85</xref>].</p>  
       <p>One possible explanation for these findings is the high fructose content in 
sugary soft drinks. Fructose has been shown to raise the risk of kidney stone 
formation, likely due to its impact on uric acid metabolism and urinary 
composition.</p>  
     </sec>  
     <sec id="S13_6">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Tea and coffee</title>  
       <p>Tea and coffee rank among the most commonly consumed beverages worldwide. 
According to comprehensive reviews and large population-based studies, regular 
consumption of tea and coffee may help reduce the risk of kidney stone formation. 
This protective effect is thought to be largely due to caffeine&#x2019;s mild diuretic 
action, which may help offset the calcium loss in urine (hypercalciuria) often 
linked with stone development [<xref ref-type="bibr" rid="ref86">86</xref>].</p>  
       <p>The European Food Safety Authority (EFSA) has deemed a daily caffeine intake of 
up to 400 mg, roughly the amount in four cups of brewed coffee, as safe for 
healthy adults, except pregnant women. In addition to caffeine&#x2019;s diuretic effect, 
tea might offer further protective benefits by increasing overall fluid 
consumption and through the antioxidant activity of its natural compounds, such 
as polyphenols.</p>  
       <p>However, many of the cohort studies did not distinguish between different types 
of tea and coffee, such as black, green, herbal, or fruit tea, which limits the 
precision of their findings. Another concern is the oxalate content present in 
these beverages. While coffee contains relatively low levels of oxalate, black 
and green teas vary significantly in oxalate concentration, depending on factors 
like plant type, harvest timing, and processing methods [<xref ref-type="bibr" rid="ref87">87</xref>]. Among the teas, 
black and green varieties tend to have the highest oxalate levels, whereas herbal 
and fruit teas are typically much lower.</p>  
       <p>Because of these variations, the exact role and mechanism by which black and 
green tea may help prevent kidney stones remain unclear and warrant further 
investigation.</p>  
     </sec>  
     <sec id="S13_7">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Sodium and calcium chloride</title>  
       <p>When daily calcium intake increases from 400 mg to 1200 mg, urinary calcium 
excretion also rises from 120 mg to 180 mg in healthy individuals, and from 240 
mg to 400 mg in those with hypercalciuria. Traditionally, people prone to kidney 
stones have been advised to reduce their intake of milk and dairy products [<xref ref-type="bibr" rid="ref88">88</xref>]. 
However, current research does not support this recommendation for several 
reasons:</p>  
       <p>1. Cutting down on calcium reduces its binding with oxalate in the gut, which 
leads to greater oxalate absorption and a higher risk of stone formation.</p>  
       <p>2. Avoiding dairy may lead patients to increase their consumption of animal 
protein (such as meat, fish, and poultry), which can negatively affect kidney 
stone risk.</p>  
       <p>Studies suggest that consuming around 1000 mg of calcium per day can lower the 
risk of kidney stones by about 30% compared to those who take in less than 600 
mg daily. A five-year randomized clinical trial involving male patients with high 
urinary calcium showed that a diet with normal calcium intake but reduced salt 
and animal protein was more effective in preventing stone recurrence than a 
low-calcium diet [<xref ref-type="bibr" rid="ref89">89</xref>].</p>  
       <p>The calcium-excreting effect of table salt is believed to come from its sodium 
and chloride content, which may impair calcium reabsorption in the kidneys. This, 
along with the acid load from proteins, can increase the risk of stone formation. 
Moreover, excess acid and potassium deficiency may reduce urinary citrate levels, 
a natural inhibitor of kidney stone formation, thereby contributing further to 
the risk of stone development [<xref ref-type="bibr" rid="ref90">90</xref>].</p>  
     </sec>  
     <sec id="S13_8">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Citrate</title>  
       <p>Citrate plays a key role in preventing the formation of calcium oxalate kidney 
stones by binding to free calcium ions in the urine. This reduces the saturation 
of calcium oxalate and prevents crystal formation. A condition known as 
hypocitraturia or low urinary citrate is commonly observed in people with calcium 
kidney stones, affecting approximately 19% to 63% of such individuals [<xref ref-type="bibr" rid="ref91">91</xref>]. As 
a result, measuring urinary citrate has become a standard part of the metabolic 
evaluation in stone-forming patients. In many cases, hypocitraturia can be 
corrected through oral alkali therapy, even though not all tissues respond 
uniformly to alkali loading. 
</p>  
       <p>The most frequent cause of low urinary citrate is metabolic acidosis, which 
alters how citrate is processed in the kidneys. Under acidic conditions, more 
citrate converts to its divalent form in the proximal tubules, where it is 
readily reabsorbed through the Sodium-dependent dicarboxylate transporter 1 
(NADC-1) transporter, a protein also found in the small intestine and colon [<xref ref-type="bibr" rid="ref92">92</xref>]. 
Research has linked NADC-1 deficiency to an increased risk of kidney stone 
formation in both human and animal studies. Acidic body conditions tend to lower 
urinary citrate levels.</p>  
       <p>A diet low in fruits and vegetables can contribute to hypocitraturia because 
these foods supply dietary alkali. Their absence leads to a more acidic internal 
environment, which encourages the kidneys to reabsorb more citrate rather than 
excrete it. Including more fruits and vegetables in the diet helps increase 
citrate levels in the urine by lowering hydrogen ion (H&#x207A;) concentration, raising 
urinary pH, and reducing citrate reabsorption.</p>  
       <p>For individuals with low citrate levels, a diet rich in fruits and vegetables is 
recommended. Such a diet not only boosts urinary volume and citrate levels but 
also provides beneficial alkaline minerals like potassium and magnesium. This 
dietary approach typically involves reducing animal protein and salt intake as 
well [<xref ref-type="bibr" rid="ref93">93</xref>]. Adherence to a DASH (Dietary Approaches to Stop Hypertension) diet 
significantly increased urinary output, even without increased fluid intake. The 
high water content and alkaline nature of fruits and vegetables likely account 
for the observed rise in urine citrate and volume. Multiple studies suggest that 
the stone-preventing effects of vegetables are due to these beneficial metabolic 
changes.</p>  
     </sec>  
     <sec id="S13_9">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Protein</title>  
       <p>For adults, the recommended protein intake is about 0.8 to 1.0 grams per 
kilogram of ideal body weight per day. Consuming excessive protein has been 
linked to changes in urine composition that may raise the risk of kidney stone 
formation. A high-protein diet increases the body&#x2019;s acid load, which can lead to 
higher urinary calcium levels, lower urine pH, and reduced citrate excretion, all 
of which are known risk factors for stone development [<xref ref-type="bibr" rid="ref94">94</xref>].</p>  
       <p>In one study involving 18 patients with hypercalciuria and kidney stones, 
reducing protein intake to 0.8 g/kg of body weight per day resulted in lower 
urinary calcium and uric acid levels, along with an increase in urinary citrate 
excretion. However, systematic reviews have provided mixed results regarding the 
link between dietary protein and stone risk. For example, a review by Pedersen 
included two large cohort studies that found no significant association between 
protein intake and kidney stone development. On the other hand, one well-designed 
study did report that higher protein intake was associated with increased urinary 
calcium levels, which could promote calcium stone formation [<xref ref-type="bibr" rid="ref95">95</xref>].</p>  
       <p>In healthy individuals, supplementation with 1.5 grams of L-methionine daily had 
no effect on calcium excretion, but increasing the dose to 3 grams per day 
resulted in a calcium excretion increase of about 1 mmol per day. So far, no 
randomized controlled trial has directly compared high versus low protein intake 
in relation to kidney stone formation risk.</p>  
       <p>Although the precise relationship between protein consumption and stone risk 
remains uncertain, large observational studies have shown that a higher dietary 
acid load, primarily from protein-rich foods, is linked with increased risk of 
stone formation [<xref ref-type="bibr" rid="ref96">96</xref>]. Importantly, the balance of protein with alkaline foods 
like fruits and vegetables may be more predictive of stone risk than protein 
alone. These plant-based foods help neutralize the acid load from proteins and 
support higher urine pH and citrate excretion.</p>  
       <p>In patients with low urinary citrate, adding more fruits and vegetables to the 
diet has been shown to raise urinary pH, boost citrate levels, and reduce the 
relative supersaturation of both calcium oxalate and uric acid. Since a highly 
acidic diet lowers both urinary pH and citrate two important defenses against 
stone formation, maintaining a diet rich in alkalizing foods is beneficial [<xref ref-type="bibr" rid="ref97">97</xref>]. 
Higher urine pH not only promotes the excretion of stone-inhibiting citrate but 
also enhances calcium binding in the urine, thereby lowering the risk of crystal 
formation.</p>  
     </sec>  
     <sec id="S13_10">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Carbohydrates</title>  
       <p>Research exploring the relationship between carbohydrate intake and kidney stone 
risk has produced mixed findings. Some studies reported that individuals with 
kidney stones consumed similar amounts of carbohydrates as healthy controls, 
while others observed higher carbohydrate intake among stone formers. A major 
limitation of these studies is their failure to differentiate between types of 
carbohydrates, especially the common disaccharide sucrose and its components, 
glucose and fructose [<xref ref-type="bibr" rid="ref98">98</xref>].</p>  
       <p>Prospective cohort studies have shown that higher sucrose intake is associated 
with an increased risk of kidney stone formation in women, though no such link 
was observed in men. Earlier research revealed that consuming 100 grams of 
glucose or sucrose increased urinary calcium excretion in both healthy 
individuals and calcium oxalate stone formers with the latter group showing a 
more pronounced effect. This rise in urinary calcium was believed to result from 
enhanced calcium absorption in the intestines and reduced reabsorption in the 
kidney tubules following a glucose load [<xref ref-type="bibr" rid="ref99">99</xref>].</p>  
       <p>It has been suggested that this effect may be partly driven by elevated insulin 
levels in response to sugar intake. However, a controlled study involving calcium 
stone patients with idiopathic hypercalciuria and healthy participants on a fixed 
diet found that high insulin levels (hyperinsulinemia) are unlikely to play a 
major role in the stone formation process in these patients.</p>  
       <p>Fructose consumption has increased significantly in recent decades due to its 
widespread use as a sweetener in processed foods and beverages, often replacing 
glucose or sucrose [<xref ref-type="bibr" rid="ref100">100</xref>]. A systematic review and meta-analysis found a positive 
association between fructose intake and kidney stone risk, although the exact 
biological mechanisms remain unclear. Fructose may contribute to stone formation 
by influencing the urinary excretion of calcium, oxalate, and uric acid, altering 
urine pH, and affecting uric acid metabolism.</p>  
       <p>Furthermore, a cohort study involving male participants linked higher fructose 
intake to an increased risk of developing gout, a condition closely tied to 
elevated uric acid levels [<xref ref-type="bibr" rid="ref101">101</xref>]. To fully understand how sugars like sucrose, 
glucose, and fructose affect stone formation, more controlled studies using fixed 
metabolic diets are needed. Such studies could clarify how these sugars influence 
urinary chemistry and the risk of forming uric acid or calcium oxalate stones 
[<xref ref-type="bibr" rid="ref102">102</xref>].</p>  
     </sec>  
     <sec id="S13_11">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Fat</title>  
       <p>The connection between dietary fat intake and the risk of developing kidney 
stones remains unclear and poorly studied. Some research found no significant 
difference in fat consumption between individuals with kidney stones and healthy 
controls, while other studies reported higher fat intake among stone formers.</p>  
       <p>Emerging evidence suggests that the type of fat consumed, particularly the 
balance between omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids 
(PUFAs), may play a role in calcium oxalate stone formation through complex 
biological pathways [<xref ref-type="bibr" rid="ref103">103</xref>]. For instance, individuals with idiopathic calcium 
oxalate stones have been found to have elevated levels of arachidonic acid 
(C20:4n-6) in their blood plasma and red blood cell membrane phospholipids 
compared to healthy people. 
</p>  
       <p>Arachidonic acid, stored in cell membrane phospholipids, can be released by 
phospholipase enzymes and converted into prostaglandin E2 (PGE2), a compound 
linked to increased urinary calcium loss. PGE2 may promote calcium stone 
formation by enhancing calcium absorption in the intestines, stimulating bone 
calcium release, and reducing the kidneys&#x2019; ability to reabsorb calcium [<xref ref-type="bibr" rid="ref104">104</xref>]. 
High levels of arachidonic acid might also contribute to elevated urinary oxalate 
by enhancing oxalate transport across the intestinal and renal membranes through 
activation of anion transporters.</p>  
       <p>In a small study involving 20 healthy participants, supplementation with omega-3 
fatty acids, specifically DHA (docosahexaenoic acid, 22:6n-3) and EPA 
(eicosapentaenoic acid, 20:5n-3) led to their incorporation into cell membrane 
phospholipids, replacing some of the arachidonic acid content [<xref ref-type="bibr" rid="ref105">105</xref>]. This dietary 
shift in fatty acid composition is believed to help reduce the urinary excretion 
of both calcium and oxalate, potentially lowering the risk of stone formation.</p>  
     </sec>  
     <sec id="S13_12">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Dietary management</title>  
       <p>Making changes to the diet is one of the most effective strategies to lower 
urinary risk factors associated with kidney stone formation, particularly calcium 
oxalate stones, which are the most common type. However, dietary recommendations 
should be personalized based on each patient&#x2019;s specific biochemical and dietary 
risk profile [<xref ref-type="bibr" rid="ref106">106</xref>]. Conducting a comprehensive nutritional assessment is an 
essential part of evaluating patients who form stones and is fundamental to 
providing effective dietary guidance.</p>  
       <p>Among the tools available, seven-day dietary records are considered the most 
reliable for assessing typical eating habits and identifying nutritional patterns 
linked to stone risk [<xref ref-type="bibr" rid="ref107">107</xref>]. Multiple dietary factors, such as fluid intake, 
protein, carbohydrate, oxalate, calcium, and sodium chloride consumption, 
significantly impact urine composition and influence the likelihood of kidney 
stone development. <xref ref-type="table" rid="T7">Table 7</xref> outlines detailed dietary guidelines tailored for 
individuals prone to calcium oxalate stones, helping to modify these key dietary 
elements to reduce stone recurrence and improve overall urinary health 
[<xref ref-type="bibr" rid="ref108">108</xref>, <xref ref-type="bibr" rid="ref109">109</xref>, <xref ref-type="bibr" rid="ref110">110</xref>].</p>  

<table-wrap id="T7" orientation="portrait" position="float">
<label>Table 7.</label>
<caption>
<p>Dietary recommendations based on urinary risk factors for 
calcium oxalate stone formers.</p></caption> 
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">Urinary Risk Factor</th> 
<th align="center">Definition/Limit</th> 
<th align="center">Dietary and Lifestyle Recommendations</th></tr> 
</thead>
<tbody valign="top">
<tr> 
<td align="left">Low Urine Volume</td> 
<td align="center">Urine output &lt;2.0 L/d</td> 
<td align="center">Increase fluid intake to achieve &gt;2.0&#x2013;2.5 L urine per day. Emphasize neutral or alkalizing fluids (<italic>e.g.</italic>, water, citrus-based beverages).</td></tr> 
<tr> 
<td align="left">Hypercalciuria</td> 
<td align="center">Urinary calcium &gt;5 mmol/d</td> 
<td align="center">Maintain daily calcium intake at 1000&#x2013;1200 mg. Limit sodium chloride and moderate protein intake (0.8&#x2013;1.0 g/kg body weight/day). Avoid excess salt and animal protein.</td></tr> 
<tr> 
<td align="left">Hyperoxaluria</td> 
<td align="center">Urinary oxalate &gt;0.5 mmol/d</td> 
<td align="center">Adopt a low-oxalate diet. Ensure adequate calcium intake (1000&#x2013;1200 mg/d) to bind oxalate in the gut. Consider calcium supplements with meals in cases of enteric hyperoxaluria.</td></tr> 
<tr> 
<td align="left">Hyperuricosuria</td> 
<td align="center">Urinary uric acid &gt;4 mmol/d</td> 
<td align="center">Reduce dietary purines (avoid red meat, organ meats, anchovies, <italic>etc.</italic>). Moderate protein intake (0.8&#x2013;1.0 g/kg body weight/day). Increase fruit and vegetable consumption.</td></tr> 
<tr> 
<td align="left">Hypocitraturia</td> 
<td align="center">Urinary citrate &lt;1.7 mmol/d</td> 
<td align="center">Increase intake of fruits and vegetables rich in citrate and potassium. Limit animal protein intake (0.8&#x2013;1.0 g/kg body weight/day). Encourage alkaline-promoting diets (<italic>e.g.</italic>, DASH or Mediterranean).</td></tr> 
 
</tbody>
</table>
<table-wrap-foot>
<fn id="TF1-1"><p>DASH: Dietary Approaches to Stop Hypertension.</p></fn></table-wrap-foot>
</table-wrap>  
     </sec>  
   </sec>  
   <sec id="S14">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Preliminary findings on dietary plants in preventing and managing 
kidney stones</title>  
     <p>Recent evidence from human studies suggests that a diet rich in fruits and 
vegetables may play a key role in preventing kidney stone formation, also known 
as urolithiasis. Large-scale population studies have identified diet as a major 
contributing factor in kidney health and disease risk [<xref ref-type="bibr" rid="ref111">111</xref>]. Smaller clinical 
trials indicate that diets emphasizing plant-based proteins rather than those 
derived from animals can help reduce the body&#x2019;s acid levels, slow down kidney 
damage in people with chronic kidney disease, and improve glomerular filtration 
rate (GFR). These plant-based dietary approaches, especially when combined with 
sodium-based alkali supplements, are considered important preventive strategies 
for individuals with reduced kidney function [<xref ref-type="bibr" rid="ref112">112</xref>].</p>  
     <p>Regular consumption of a plant-based diet has been shown to raise urine pH and 
increase urine output. It also boosts the levels of natural stone-preventing 
substances in the urine, such as citrate, phytate, potassium, and magnesium. 
These components help to reduce the supersaturation of calcium oxalate and uric 
acid, which are the primary compounds involved in kidney stone formation. Phytate 
a naturally occurring form of phosphate in plant foods has been found to bind 
with calcium in the digestive tract, lowering the chances of crystal formation in 
the urine and thus reducing stone risk. Moreover, plant-derived alkaline 
compounds enhance urinary citrate levels, a known inhibitor of stone development 
[<xref ref-type="bibr" rid="ref113">113</xref>].</p>  
     <p>In addition, dietary fiber abundant in fruits and vegetables may further support 
kidney stone prevention. Fiber binds with minerals and fats in the intestines, 
which can reduce the amount of oxalate and calcium that enters the urine. A study 
examining the dietary habits of women found that those who consumed more 
plant-based foods, fruits, and vegetables were less likely to have a history of 
kidney stones [<xref ref-type="bibr" rid="ref114">114</xref>]. Even among women who had previously experienced stones, 
increased intake of these foods was associated with a lower risk of recurrence.</p>  
   </sec>  
   <sec id="S15">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Role of dietary plants in preventing kidney stones</title>  
     <p>Using dietary strategies is considered an effective and practical approach to 
protect kidney health. These interventions can work alone or alongside genetic 
and lifestyle factors to help prevent kidney stones. Plant-based nutrition, in 
particular, has shown promise in reducing the recurrence of calcium oxalate 
stones, the most common type of kidney stones [<xref ref-type="bibr" rid="ref115">115</xref>].</p>  
     <p>In the following section, we explore a variety of dietary plants, natural food 
additives, fruits, and vegetables that have demonstrated protective effects 
against kidney stone formation. Each of these natural agents offers specific 
benefits that contribute to the prevention of urolithiasis, supported by 
experimental and clinical evidence.</p>  
     <sec id="S15_1">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Green tea</title>  
       <p>Green tea (<italic>Camellia sinensis</italic>) has been widely used as a traditional 
remedy due to its rich content of polyphenols, which give it strong antioxidant 
properties. Although green tea naturally contains oxalates and may not be ideal 
for individuals prone to calcium oxalate kidney stones, it has still attracted 
considerable interest as a dietary supplement for those with kidney stone issues. 
This is because of its potential anti-stone (antilithogenic), heart-protective 
(anti-atherosclerotic), and antioxidant effects [<xref ref-type="bibr" rid="ref116">116</xref>].</p>  
       <p>Key compounds in green tea, known as catechins such as epigallocatechin gallate 
(EGCG), epicatechin gallate (ECG), epigallocatechin (EGC), and epicatechin (EC), 
have been found to guard the kidneys against oxalate damage. Experimental studies 
in rats showed that green tea intake reduced the supersaturation of brushite (a 
type of calcium phosphate), lowered the expression of osteopontin (OPN) and 
superoxide dismutase (SOD), improved the Bcl-2 protein levels, and reduced kidney 
cell death (apoptosis) [<xref ref-type="bibr" rid="ref117">117</xref>].</p>  
       <p>Overall, these findings suggest that green tea, because of its antioxidant 
components, may help lower the formation of calcium-based kidney stones.</p>  
     </sec>  
     <sec id="S15_2">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Raspberry</title>  
       <p>Raspberry (<italic>Rubus idaeus</italic>), a fruit from the Rosaceae family, is widely 
cultivated in parts of Europe and the Mediterranean region and has long been 
valued for its nutritional and medicinal benefits. Recent studies suggest that 
raspberries may help reduce the risk of kidney stones, even after short-term use 
[<xref ref-type="bibr" rid="ref118">118</xref>].</p>  
       <p>Research has shown that raspberries are particularly effective against calcium 
oxalate stones the most common type of kidney stone. In animal studies, the 
aqueous extract of raspberry significantly reduced the buildup and 
crystallization of calcium oxalate in the kidneys. It also helped break down 
existing crystal matrices. Rats treated with raspberry extract showed lower 
levels of harmful markers such as malondialdehyde (MDA) and protein carbonyls, as 
well as decreased urinary calcium and phosphorus levels [<xref ref-type="bibr" rid="ref119">119</xref>].</p>  
       <p>These findings suggest that raspberries may offer protective benefits against 
kidney stone formation through their antioxidant and crystal-inhibiting effects.</p>  
     </sec>  
     <sec id="S15_3">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>  
         <italic>Rubia cordifolia</italic>  
       </title>  
       <p><italic>Rubia cordifolia</italic>, commonly known as madder or Indian madder, belongs to 
the Rubiaceae (coffee) family and has traditionally been used as a natural dye in 
foods. Phytochemical studies of <italic>R. cordifolia</italic> have shown that it 
contains several beneficial compounds, such as glycosides, triterpenoids, 
anthraquinones, saponins, quinones, and tannins. These bioactive components have 
made the plant useful in managing a wide range of health conditions, including 
jaundice, diabetic foot ulcers, and cardiovascular problems [<xref ref-type="bibr" rid="ref120">120</xref>].</p>  
       <p>In addition to these benefits, <italic>R. cordifolia</italic> has shown potential in 
supporting kidney health and preventing the formation of urinary stones. Its 
extract helps reduce the development and accumulation of calcium oxalate crystals 
in the kidneys. This effect may be due to its ability to restore magnesium 
levels, reduce protein loss in urine (proteinuria), and lower uric acid excretion 
[<xref ref-type="bibr" rid="ref121">121</xref>]. Its antioxidant properties likely contribute to its overall 
kidney-protective (nephroprotective) action.</p>  
     </sec>  
     <sec id="S15_4">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Parsley</title>  
       <p>Parsley (<italic>Petroselinum crispum</italic>), a versatile plant from the Umbelliferae 
family, is commonly used as an herb, spice, and vegetable across Western Asia, 
the Mediterranean, and Europe. Research has highlighted its numerous health 
benefits, including antioxidant, anti-inflammatory, diuretic, kidney-protective 
(nephroprotective), enzyme-regulating, and blood pressure-lowering effects [<xref ref-type="bibr" rid="ref122">122</xref>]. 
These properties are largely attributed to its rich content of bioactive 
compounds such as flavonoids, carotenoids, coumarins, tocopherol (vitamin E), and 
ascorbic acid (vitamin C).</p>  
       <p>Parsley has also been recognized for its potential to help prevent kidney 
stones. In animal models of calcium oxalate stone formation, parsley extract 
significantly reduced the formation of calcium oxalate crystals, decreased urine 
supersaturation, and lowered protein excretion in urine [<xref ref-type="bibr" rid="ref123">123</xref>]. Its high content 
of chlorophyll and magnesium is thought to reduce the risk of stone development 
by preventing oxalate overload and dehydration of crystals. Additionally, parsley 
helps maintain an optimal urine pH, which keeps calcium oxalate particles 
dispersed and easier to eliminate from the urinary system.</p>  
     </sec>  
     <sec id="S15_5">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>Pomegranate (<italic>punica granatum</italic>)</title>  
       <p>Pomegranate (<italic>Punica granatum</italic>) has a long history of use in traditional 
medicine and is often referred to as &#x201C;a pharmacy in itself&#x201D; due to its wide 
range of therapeutic compounds. The fruit is rich in powerful antioxidants such 
as polyphenols, anthocyanins, and alkaloids, which help neutralize harmful free 
radicals [<xref ref-type="bibr" rid="ref124">124</xref>]. Almost every part of the plant, including its seeds, juice, peel, 
flowers, and seed oil, has been used for both preventive and therapeutic 
purposes.</p>  
       <p>In traditional practices, pomegranate seeds are used to ease urinary discomfort 
and burning sensations. Its juice and extracts have been employed to protect the 
kidneys from toxic damage, while the peel and flowers have shown potential in 
treating kidney dysfunction and supporting renal artery health. One of the most 
notable benefits of pomegranate is its ability to reduce excessive calcium levels 
in urine (anti-hypercalciuria) and prevent the formation of kidney stones 
(anti-urolithiasis), making it a valuable natural agent in the prevention of 
renal stone formation.</p>  
     </sec>  
     <sec id="S15_6">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>  
         <italic>Ammi visnaga</italic>  
       </title>  
       <p><italic>Ammi visnaga</italic> has been used for centuries in Egyptian traditional 
medicine, particularly in the form of herbal teas made from its fruits, to treat 
kidney stones. Research has shown that an aqueous extract from this plant can 
help speed up the breakdown of cystine stones.</p>  
       <p>Two of its primary active compounds, khellin and visnagin, have demonstrated 
beneficial effects in managing kidney stone formation caused by hyperoxaluria in 
experimental models. In male rats, these compounds helped reduce the build-up of 
calcium oxalate crystals, increased the excretion of citrate (a natural inhibitor 
of stone formation), and lowered the amount of oxalate excreted in urine [<xref ref-type="bibr" rid="ref125">125</xref>]. 
These findings highlight <italic>Ammi visnaga</italic> as a promising natural approach to 
preventing and treating certain types of kidney stones.</p>  
     </sec>  
     <sec id="S15_7">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>  
         <italic>Nigella sativa</italic>  
       </title>  
       <p><italic>Nigella sativa</italic>, commonly known as black seed, has been widely used in 
Iranian traditional medicine to help treat urinary stones. Scientific studies 
using ethylene glycol-induced kidney stone models in rats have shown that 
ethanolic extracts of <italic>Nigella sativa</italic> seeds significantly reduced the 
formation of calcium oxalate deposits in both the kidneys and the urine.</p>  
       <p>The herb&#x2019;s main active compound, thymoquinone, displayed both preventive 
(prophylactic) and treatment (therapeutic) properties against kidney stone 
formation. In animal studies, thymoquinone effectively decreased the size and 
number of calcium oxalate crystals within the renal tubules, demonstrating its 
potential as a natural remedy for managing and preventing kidney calculi [<xref ref-type="bibr" rid="ref126">126</xref>].</p>  
     </sec>  
     <sec id="S15_8">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>  
         <italic>Hibiscus sabdariffa</italic>  
       </title>  
       <p><italic>Hibiscus sabdariffa</italic>, widely recognized in traditional Thai medicine, 
has long been used for both the treatment and prevention of urinary stones. This 
medicinal plant is rich in active compounds, including polyphenols, anthocyanins, 
vitamin C (L-ascorbic acid), quercetin, and protocatechuic acid.</p>  
       <p>Experimental studies have demonstrated that aqueous extracts of <italic>Hibiscus 
sabdariffa</italic> exhibit strong antiurolithiatic effects. In animal models where 
kidney stones were induced using ethylene glycol, the extract significantly 
reduced the accumulation of stone-forming substances in the kidneys and blood 
serum [<xref ref-type="bibr" rid="ref127">127</xref>]. Additionally, in rats fed a glycolate-enriched diet, the extract 
helped reduce oxalate retention time in the kidneys and promoted its excretion 
through urine, showing clear potential in limiting stone formation.</p>  
     </sec>  
     <sec id="S15_9">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>  
         <italic>Origanum vulgare</italic>  
       </title>  
       <p><italic>Origanum vulgare</italic>, commonly known as oregano, has been traditionally 
used as a lithotriptic (stone-dissolving agent), diuretic, antispasmodic, and 
culinary spice. Scientific studies have shown that a crude aqueous-methanolic 
extract of the aerial parts of this plant can inhibit the formation and 
clustering of calcium oxalate crystals in laboratory (<italic>in vitro</italic>) 
settings, significantly reducing crystal development in calcium oxalate 
supersaturated solutions [<xref ref-type="bibr" rid="ref128">128</xref>].</p>  
       <p>Animal studies using ethylene glycol and ammonium chloride to induce kidney 
stones demonstrated that this extract exerted a strong antiurolithic effect, 
likely by preventing crystal growth, protecting kidney cells, and offering 
antioxidant and antispasmodic properties [<xref ref-type="bibr" rid="ref129">129</xref>]. These protective actions are 
believed to stem from the plant&#x2019;s diverse bioactive compounds, including 
flavonoids, terpenes, coumarins, saponins, alkaloids, sterols, and tannins.</p>  
     </sec>  
   </sec>  
   <sec id="S16">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Strategies to prevent kidney stones (urolithiasis)</title>  
     <p>Preventing kidney stones starts with identifying and addressing their root 
causes. Whether someone is trying to prevent their first stone or avoid a 
recurrence, dietary adjustments and proper medication use are essential. Since 
these approaches are affordable and widely applicable, they offer significant 
public health benefits. Among all strategies, dietary changes are the most 
effective in preventing kidney stones.</p>  
     <p>One of the most important lifestyle changes is to increase fluid intake, 
ensuring that urine output stays above 2 liters per day. More water helps dilute 
stone-forming substances like calcium oxalate and reduces the concentration of 
these crystals in the urine [<xref ref-type="bibr" rid="ref130">130</xref>].</p>  
     <p>Dietary recommendations must be tailored to each individual based on their 
metabolic risk factors. For example, in people with absorptive hyperoxaluria, 
reducing foods high in oxalate while maintaining adequate dietary calcium can 
help. Calcium binds to oxalate in the gut, reducing its absorption and risk of 
stone formation.</p>  
     <p>A high-salt diet can raise calcium levels in urine by interfering with calcium 
reabsorption in the kidneys, so it&#x2019;s wise to cut back on sodium. Similarly, 
animal protein (such as meat, fish, and poultry), which contains sulfur-rich 
amino acids, can increase the acid load in the body. This may result in lower 
urine pH and reduced citrate levels, both of which contribute to stone formation.</p>  
     <p>If the urine becomes too acidic, limiting animal protein and vitamin D-rich 
foods may help, while increasing the intake of potassium-rich fruits and 
vegetables can restore balance.</p>  
     <p>It&#x2019;s also important to note that cutting calcium too much can backfire. Low 
calcium intake may increase the body&#x2019;s absorption of dietary oxalate, leading to 
more oxalate in the urine and a higher risk of stones. Calcium supplements, when 
taken with meals, may help by binding oxalate in the gut. However, the benefits 
of calcium supplements remain uncertain.</p>  
     <p>In addition, excessive vitamin C (ascorbic acid) can be converted into oxalate 
in the body, so its intake should be kept in check [<xref ref-type="bibr" rid="ref131">131</xref>].</p>  
     <p>To prevent stones like calcium oxalate, uric acid, and cystine, the goal is to 
alkalize the urine using fruits, vegetables, citrate supplements, or alkaline 
mineral water. For those prone to uric acid stones, managing gout is vital, and 
for cystine stones, limiting salt and protein is recommended.</p>  
     <p>In contrast, acidic urine helps prevent calcium phosphate and struvite stones. 
For struvite stones, acidifying urine is a key treatment strategy. Regular 
follow-up care is essential to confirm that infections are cleared, as infections 
can contribute to stone formation.</p>  
     <p>Unfortunately, current medications are often insufficient to fully prevent 
kidney stones, which highlights the need for further research and new therapeutic 
options [<xref ref-type="bibr" rid="ref132">132</xref>].</p>  
   </sec>  
   <sec id="S17">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Urological interventions in kidney stone management</title>  
     <p>Surgical intervention becomes necessary when medical treatments fail or 
emergency decompression is required [<xref ref-type="bibr" rid="ref133">133</xref>, <xref ref-type="bibr" rid="ref134">134</xref>, <xref ref-type="bibr" rid="ref135">135</xref>, <xref ref-type="bibr" rid="ref136">136</xref>, <xref ref-type="bibr" rid="ref137">137</xref>, <xref ref-type="bibr" rid="ref138">138</xref>, <xref ref-type="bibr" rid="ref139">139</xref>]. However, there is no universally 
accepted timeline for when to proceed with surgical procedures [<xref ref-type="bibr" rid="ref140">140</xref>, <xref ref-type="bibr" rid="ref141">141</xref>, <xref ref-type="bibr" rid="ref142">142</xref>, <xref ref-type="bibr" rid="ref143">143</xref>, <xref ref-type="bibr" rid="ref144">144</xref>, <xref ref-type="bibr" rid="ref145">145</xref>] (see 
<xref ref-type="table" rid="T8">Table 8</xref>). The three primary treatment options include Extracorporeal Shock Wave 
Lithotripsy (ESWL), Ureteroscopy (URS), and 
Percutaneous Nephrolithotomy (PCNL). The choice of procedure depends on factors 
like stone size, location, the surgeon&#x2019;s expertise, and the availability of 
specialized equipment.</p>  

<table-wrap id="T8" orientation="portrait" position="float">
<label>Table 8.</label>
<caption>
<p>Comparative overview of therapeutic modalities for renal and 
ureteral stone management.</p></caption> 
<table frame="border" rules="all">
<thead valign="top"> 
<tr> 
<th align="left">Treatment Modality</th> 
<th align="center">Indication</th> 
<th align="center">Stone-Free Rate (%)</th> 
<th align="center">Limitations</th> 
<th align="center">Complications</th></tr> 
</thead> 
<tbody valign="top">
<tr> 
<td align="left">Shock Wave Lithotripsy (SWL)</td> 
<td align="center">Small renal and ureteral stones</td> 
<td align="center">80&#x2013;83</td> 
<td align="center">No direct visualization; high retreatment rate</td> 
<td align="center">Steinstrasse, perirenal hemorrhage</td></tr> 
<tr> 
<td align="left">Ureteroscopy (URS)</td> 
<td align="center">Small-to-medium renal and ureteral stones</td> 
<td align="center">85&#x2013;88</td> 
<td align="center">Requires adult-sized equipment; operator-dependent technique</td> 
<td align="center">Ureteral perforation, infection, strictures, hematuria</td></tr> 
<tr> 
<td align="left">Percutaneous Nephrolithotomy (PCNL)</td> 
<td align="center">Large/complex renal calculi (&gt;2 cm), staghorn stones</td> 
<td align="center">70&#x2013;97</td> 
<td align="center">Invasive; requires general anesthesia, surgical expertise, and hospitalization</td> 
<td align="center">Bleeding (8&#x2013;16% transfusion), urinary leakage, fever, sepsis</td></tr> 
<tr> 
<td align="left">Mini-PCNL/Ultra-Mini PCNL</td> 
<td align="center">Medium-sized renal stones (1&#x2013;2 cm)</td> 
<td align="center">82&#x2013;95</td> 
<td align="center">Narrow working channel; limited in large stone burden</td> 
<td align="center">Similar to PCNL but lower bleeding risk</td></tr> 
<tr> 
<td align="left">Open Pyelolithotomy</td> 
<td align="center">Very large or multiple complex stones</td> 
<td align="center">79&#x2013;98</td> 
<td align="center">Highly invasive; longer hospital stay and recovery time</td> 
<td align="center">Risks of open surgery: infection, scarring, delayed recovery</td></tr> 
<tr> 
<td align="left">Minimally Invasive Pyelolithotomy</td> 
<td align="center">Large renal stones (in selected cases)</td> 
<td align="center">Not well documented</td> 
<td align="center">Learning curve; limited literature</td> 
<td align="center">Similar to other minimally invasive procedures</td></tr> 
<tr> 
<td align="left">Laparoscopic Pyelolithotomy</td> 
<td align="center">Large solitary stones not amenable to SWL/URS</td> 
<td align="center">85&#x2013;95</td> 
<td align="center">Technically demanding; requires advanced laparoscopic skills</td> 
<td align="center">Injury to adjacent structures, prolonged anesthesia</td></tr> 
<tr> 
<td align="left">Robotic-Assisted Stone Removal</td> 
<td align="center">Large impacted stones with anatomical challenges</td> 
<td align="center">~90</td> 
<td align="center">High cost, limited availability in low-resource settings</td> 
<td align="center">Same as laparoscopic; reduced tactile feedback</td></tr> 
<tr> 
<td align="left">Medical Expulsive Therapy (MET)</td> 
<td align="center">Small distal ureteric stones (&lt;10 mm)</td> 
<td align="center">35&#x2013;65</td> 
<td align="center">Limited to select cases; slower response</td> 
<td align="center">Delayed stone passage may lead to obstruction or infection</td></tr> 
<tr> 
<td align="left">Anatrophic Nephrolithotomy</td> 
<td align="center">Complex staghorn calculi in non-functioning kidneys</td> 
<td align="center">70&#x2013;90</td> 
<td align="center">Major surgery; risk of renal ischemia</td> 
<td align="center">Hemorrhage, renal impairment, infection</td></tr> 
</tbody> 
</table></table-wrap>  
     <sec id="S17_1">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>ESWL (extracorporeal shock wave lithotripsy)</title>  
       <p>ESWL is often preferred for treating small stones in the upper urinary tract, 
especially in children, because it is non-invasive, relatively simple, and 
effective. In the short term, the stone-free rate ranges from 57% to 97%, and 
in the long term, between 57% and 92%. ESWL works best for stones less than 20 
mm located in the renal pelvis or calyces. Its effectiveness is lower for larger 
stones or those located in the distal ureters [<xref ref-type="bibr" rid="ref134">134</xref>].</p>  
       <p>Possible short-term side effects include blood in urine (haematuria), pain, 
fever, stone fragments blocking the ureter (steinstrasse), and small internal 
bleeds (hematomas), although these are generally rare.</p>  
       <p>The long-term safety of ESWL in children remains unclear. Most studies show no 
lasting damage to kidney structure or function in children, but these studies are 
often limited by small participant numbers and short observation periods. Some 
recent data suggests a potential link to high blood pressure following ESWL, but 
further research is needed to fully understand this risk [<xref ref-type="bibr" rid="ref135">135</xref>].</p>  
     </sec>  
     <sec id="S17_2">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>URS (ureteroscopy)</title>  
       <p>URS is another safe and effective method for treating kidney stones in infants 
and young patients, particularly for stones &#x2264;20 mm in the mid or lower 
ureter. A systematic review of over 1700 procedures showed an average stone-free 
rate of 87.5%, with a 10.5% complication rate, mostly of mild to moderate 
severity (Clavien Grade I&#x2013;III) [<xref ref-type="bibr" rid="ref136">136</xref>].</p>  
       <p>However, for children under six, URS may require pre-stenting (inserting a tube 
before the procedure) due to the increased risk of complications or failure in 
younger patients.</p>  
     </sec>  
     <sec id="S17_3">  
       <!-- The element tags   
is currently not supported for the main body. 
	-->  
       <title>PCNL (percutaneous nephrolithotomy)</title>  
       <p>PCNL is typically reserved for large stones, complex cases, blockages due to 
stones, or when other treatments do not succeed. It is especially useful for 
patients with high stone burden or persistent kidney infections caused by stones 
[<xref ref-type="bibr" rid="ref137">137</xref>].</p>  
       <p>PCNL has a high success rate (around 90%), but it also carries more significant 
risks, such as bleeding requiring transfusion, injury to surrounding organs, and 
infection [<xref ref-type="bibr" rid="ref138">138</xref>].</p>  
       <p>To reduce these risks, newer, minimally invasive forms of PCNL have been 
developed, such as mini-PCNL, ultramini-PCNL, and micro-PCNL. These techniques 
use smaller instruments, which help lower the chance of complications while still 
maintaining effective stone removal [<xref ref-type="bibr" rid="ref139">139</xref>].</p>  
     </sec>  
   </sec>  
   <sec id="S18">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Impact of vegetarian and vegan diets on kidney stone formation and 
recurrence</title>  
     <p>According to the Vegetarian Society, a vegetarian diet avoids all products that 
involve the killing of animals, such as meat, poultry, fish, and seafood [<xref ref-type="bibr" rid="ref146">146</xref>]. 
However, many vegetarians still include dairy and eggs in their meals (lacto-ovo 
vegetarians), while others ovo-vegetarians exclude dairy but continue to eat 
eggs. In contrast, vegans follow a much stricter regimen, eliminating all 
animal-based foods, including dairy and eggs [<xref ref-type="bibr" rid="ref147">147</xref>].</p>  
     <p>A review of dietary influences on kidney stone formation suggests that the most 
effective strategy for reducing stone risk involves eating a diet rich in fruits 
and vegetables, limiting animal proteins, moderate low-fat dairy intake, and low 
salt consumption [<xref ref-type="bibr" rid="ref148">148</xref>]. These recommendations closely resemble a balanced 
vegetarian diet that still includes dairy products. In comparison, vegan diets 
while plant-based tend to be higher in oxalates and lower in calcium due to the 
exclusion of dairy, which may increase the risk of calcium oxalate stone 
formation [<xref ref-type="bibr" rid="ref149">149</xref>].</p>  
     <p>Vegetarians generally consume a similar amount of calcium as the general 
population, but vegans tend to consume less calcium, potentially increasing stone 
risk. So far, no major studies have directly compared the risk of kidney stones 
in vegan versus vegetarian populations [<xref ref-type="bibr" rid="ref150">150</xref>]. However, Robertson hypothesized 
that a vegetarian lifestyle could lead to a 40% to 60% lower chance of 
developing stones compared to non-vegetarians, even when adjusting for age, 
gender, and socioeconomic differences.</p>  
     <p>In a large study from the Oxford cohort of the European Prospective 
Investigation into Cancer and Nutrition (EPIC), researchers examined how 
different diets ranging from high meat intake to vegetarianism affected kidney 
stone risk. Among over 51,000 participants, 303 new kidney stone cases were 
recorded during more than 716,000 person-years of follow-up [<xref ref-type="bibr" rid="ref151">151</xref>]. Compared to 
those who ate large amounts of meat, vegetarians and people with low meat intake 
had significantly lower risks of kidney stones, with hazard ratios of 0.69 and 
0.52, respectively. Interestingly, red meat and poultry were more strongly linked 
to stone formation than processed meats, and higher fruit consumption was linked 
to a lower risk [<xref ref-type="bibr" rid="ref152">152</xref>].</p>  
     <p>These results align with findings from studies on the DASH (Dietary Approaches 
to Stop Hypertension) and Mediterranean diets, which both emphasize plant-based 
foods. In a U.S. cohort of over 241,000 men and women, researchers tracked 
adherence to the DASH diet for up to 18 years. The diet was scored based on 
intake of fruits, vegetables, nuts, low-fat dairy, whole grains, and low 
consumption of salt, sugary drinks, and red meat [<xref ref-type="bibr" rid="ref153">153</xref>, <xref ref-type="bibr" rid="ref154">154</xref>]. Those with the 
highest DASH scores had significantly lower risks of developing stones, with 
relative risks of 0.55, 0.58, and 0.60 in men, older women, and younger women, 
respectively, compared to typical American diets [<xref ref-type="bibr" rid="ref155">155</xref>].</p>  
     <p>The Mediterranean diet, which focuses on plant-based foods and uses less red 
meat, showed similar protective benefits. In a study of 16,094 participants with 
no prior history of kidney stones, those who most closely followed the 
Mediterranean diet had hazard ratios of 0.93 and 0.64 for developing stones, 
compared to less adherent individuals [<xref ref-type="bibr" rid="ref156">156</xref>]. However, people consuming more 
monounsaturated fats compared to saturated fats were unexpectedly found to have a 
higher stone risk than those who ate more vegetables and dairy products.</p>  
     <p>Because individuals with kidney stones also face higher risks of heart disease 
and kidney failure, following the Mediterranean diet offers added benefits. 
Research shows that this eating pattern helps reduce both risks [<xref ref-type="bibr" rid="ref157">157</xref>].</p>  
     <p>Interestingly, a case-control study from China with over 2000 participants found 
that certain vegetarian-style diets might increase stone risk, particularly among 
women. Higher intake of grains and beans was associated with a greater chance of 
kidney stone development. Consuming more than three servings of green vegetables 
daily was also linked to increased stone risk in both men and women [<xref ref-type="bibr" rid="ref158">158</xref>, <xref ref-type="bibr" rid="ref159">159</xref>].</p>  
     <p>The role of dietary fiber in stone prevention remains controversial. Some 
evidence suggests that high-fiber, low-calcium diets may reduce urinary calcium 
but also raise oxalate levels, potentially increasing calcium oxalate saturation 
in urine [<xref ref-type="bibr" rid="ref160">160</xref>]. Other studies, such as the EPIC-Oxford cohort, found that fiber 
might be helpful in reducing stone risk, but vegetable intake by itself was 
neither beneficial nor harmful [<xref ref-type="bibr" rid="ref161">161</xref>, <xref ref-type="bibr" rid="ref162">162</xref>].</p>  
   </sec>  
   <sec id="S19">  
     <!-- The element tags   
is currently not supported for the main body. 
	-->  
     <title>Conclusion</title>  
     <p>Kidney stones, or renal calculi, are hard mineral deposits that form inside the 
kidneys and pose a major health challenge worldwide, impacting around 12% of 
people globally. Their development is influenced by both environmental conditions 
and metabolic disorders. Among the various types, calcium oxalate and calcium 
phosphate stones are the most common, making up about 70% of all cases, 
especially in economically advanced countries. Fortunately, preventive measures 
such as staying well-hydrated and making specific dietary changes have been shown 
to effectively reduce the chances of forming these painful stones.</p>  
     <p>Pharmacological interventions such as Thiazides, Allopurinol, Potassium Alkali, 
and Tiopronin have demonstrated clinical efficacy in reducing stone recurrence 
through mechanisms that regulate urinary excretion of minerals. In addition, 
non-pharmacological treatments utilizing herbal remedies like 
<italic>Virataradigana</italic>, <italic>Crateava nurvala</italic>, and <italic>Boerhaavia 
diffusa</italic> have shown potential in alleviating symptoms and preventing stone 
aggregation through their diuretic and antiurolithiatic properties. 
</p>  
     <p>While current evidence supports the therapeutic effectiveness of these 
interventions, further clinical trials are crucial to expanding understanding of 
both pharmacological and herbal treatments. Such studies would not only validate 
traditional approaches but also contribute to enhanced management strategies for 
nephrolithiasis. Thus, a comprehensive integration of conventional medicine and 
herbal therapeutics could pave the way for improved patient outcomes and reduced 
incidence of kidney stone recurrence.</p>  
   </sec>   

   
 </body>  
 <back> 

   
   
   <ack>
   <sec id="S20">  
 
     <title>Abbreviations</title>  
     <p id="S20.p1">CaOx, calcium oxalate; CaP, calcium phosphate; CAP, calcium phosphate stones; 
DASH, Dietary Approaches to Stop Hypertension; EC, epicatechin; ECG, epicatechin 
gallate; EGCG, epigallocatechin gallate; ESWL, extracorporeal shock wave 
lithotripsy; GFR, glomerular filtration rate; MDA, malondialdehyde; OPN, 
osteopontin; PCNL, percutaneous nephrolithotomy; PGE2, prostaglandin E2; PEM, 
protein-energy malnutrition; RIRS, retrograde intrarenal surgery; NaCl, sodium 
chloride; NADC-1, sodium dicarboxylate cotransporter 1; SOD, superoxide 
dismutase; UTI, urinary tract infection; E. coli, Escherichia 
coli; UTIs, urinary tract infections; HPFS, Health Professionals Follow-Up Study; 
NHS, Nurses&#x2019; Health Studies; NHANES, National Health and Nutrition Examination 
Survey; PUFAs, polyunsaturated fatty acids; DHA, docosahexaenoic acid; EPA, 
eicosapentaenoic acid; EGC, epigallocatechin; URS, Ureteroscopy; EPIC, European Prospective Investigation into Cancer and Nutrition; EFSA, European Food Safety Authority.</p>  
   </sec>  
   <sec id="S21">  
 
     <title>Availability of data and materials</title>  
     <p id="S21.p1">The data and supporting information are available within the article.</p>  
   </sec>  
   <sec id="S22">  
 
     <title>Author contributions</title>  
     <p id="S22.p1">PS and AP&#x2014;designed the research study; wrote the manuscript. PS&#x2014;performed the research and 
collected the data. AP&#x2014;analyzed and interpreted the results. Both authors contributed to editorial changes in the manuscript. 
Both authors read and approved the final manuscript.</p>  
   </sec>  
   <sec id="S23">  
  
     <title>Ethics approval and consent to participate</title>  
     <p id="S23.p1">The authors did not conduct any research on humans or animals for this paper.</p>  
   </sec>  
   <sec id="S24">  
  
     <title>Acknowledgment</title>  
     <p id="S24.p1">The authors gratefully acknowledge the support provided by Sanskriti College of 
Higher Education and Studies, Kanpur Dehat, Uttar Pradesh (UP) for facilitating 
this study. The institution offered administrative assistance and academic 
infrastructure that contributed to the successful completion of this work. 
</p>  
   </sec>  
   <sec id="S25">  
 
     <title>Funding</title>  
     <p id="S25.p1">This research received no specific grant from any funding agency in the public, 
commercial, or not-for-profit sectors.</p>  
   </sec>  
   <sec id="S26">  
  
     <title>Conflict of interest</title>  
     <p id="S26.p1">The authors declare no conflict of interest.</p>  
   </sec>   
   </ack>

<fn-group>
<fn id="fn1"><p><italic>How to cite:</italic> Maria Kamal, Zhongxin Yu, Neha Varshney. Liver biopsies in Pediatric patients—a histopathological review of common entities. Journal
of Renal and Hepatic Disorders. 2025; 9(1): 1-11. doi: 10.63268/jrenhp.v9i1.198.</p></fn></fn-group>
   
  
  <ref-list>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Danilovic A, Marchini GS, Pucci ND, Coimbra B, Torricelli FC, Batagello C</name></string-name></person-group>, <italic>et al</italic>.<article-title> Effect of a low-calorie diet on 24-hour urinary parameters of obese adults with idiopathic calcium oxalate kidney stones.</article-title><source> International Brazilian Journal of Urology</source>. <year>2021</year>; <volume>47</volume>: <fpage>1136</fpage>&#x2013;<lpage>1147</lpage>.</mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Wu ZB, Jiang T, Lin GB, Wang YX, Zhou Y, Chen ZQ</name></string-name></person-group>, <italic>et al</italic>.<article-title> Tea consumption is associated with increased risk of kidney stones in Northern Chinese: a cross-sectional study.</article-title><source> Biomedical and Environmental Sciences</source>. <year>2017</year>; <volume>30</volume>: <fpage>922</fpage>&#x2013;<lpage>926</lpage>.</mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Akarken I, Tarhan H, Ekin RG, Çakmak Ö, Koç G, İlbey YÖ</name></string-name></person-group>, <italic>et al</italic>.<article-title> Visceral obesity: a new risk factor for stone disease.</article-title><source> Canadian Urological Association Journal</source>. <year>2015</year>; <volume>9</volume>: <page>E795</page>.</mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Astolfi RH, Carrera R, Gattas N, Bertolla R, Sepulveda F, Reggio E</name></string-name></person-group>, <italic>et al</italic>.<article-title> Current scenario of endourological treatment of kidney stones in brazil: results of a national survey.</article-title><source> International Brazilian Journal of Urology</source>. <year>2020</year>; <volume>46</volume>: <fpage>400</fpage>&#x2013;<lpage>408</lpage>.</mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Singh P, Enders FT, Vaughan LE, Bergstralh EJ, Knoedler JJ, Krambeck AE</name></string-name></person-group>, <italic>et al</italic>.<article-title> Stone composition among first-time symptomatic kidney stone formers in the community.</article-title><source> Mayo Clinic Proceedings</source>. <year>2015</year>; <volume>90</volume>: <fpage>1356</fpage>&#x2013;<lpage>1365</lpage>.</mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ferraro PM, Curhan GC</name></string-name></person-group>.<article-title> Long-term Adverse outcomes of urolithiasis.</article-title><source> American Journal of Kidney Diseases</source>. <year>2018</year>; <volume>72</volume>: <fpage>774</fpage>&#x2013;<lpage>775</lpage>.</mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sikarwar V</name></string-name></person-group>.<article-title> Herbal remedies for kidney stone.</article-title><source> Contemporary Advances in Science &amp; Technology</source>. <year>2022</year>; <volume>5</volume>: <fpage>135</fpage>&#x2013;<lpage>142</lpage>.</mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Alelign T, Petros B</name></string-name></person-group>.<article-title> Kidney stone disease: an update on current concepts.</article-title><source> Advances in Urology</source>. <year>2018</year>; <volume>2018</volume>: <page>3068365</page>.</mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians</name></string-name></person-group>.<article-title> Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians.</article-title><source> Annals of Internal Medicine</source>. <year>2014</year>; <volume>161</volume>: <fpage>659</fpage>&#x2013;<lpage>667</lpage>.</mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Daudon M, Frochot V, Bazin D, Jungers P</name></string-name></person-group>.<article-title> Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment.</article-title><source> Drugs</source>. <year>2018</year>; <volume>78</volume>: <fpage>163</fpage>&#x2013;<lpage>201</lpage>.</mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Abbas W, Akram M, Sharif A</name></string-name></person-group>.<article-title> Nephrolithiasis; prevalence, risk factors and therapeutic strategies: a review.</article-title><source> Madridge Journal of Internal and Emergency Medicine</source>. <year>2019</year>; <volume>3</volume>: <fpage>90</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E</name></string-name></person-group>, <italic>et al</italic>.<article-title> Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.</article-title><source> Journal of Nephrology</source>. <year>2016</year>; <volume>29</volume>: <fpage>715</fpage>&#x2013;<lpage>734</lpage>.</mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ma Q, Fang L, Su R, Ma L, Xie G, Cheng Y</name></string-name></person-group>.<article-title> Uric acid stones, clinical manifestations and therapeutic considerations.</article-title><source> Postgraduate Medical Journal</source>. <year>2018</year>; <volume>94</volume>: <fpage>458</fpage>&#x2013;<lpage>462</lpage>.</mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Moe OW, Abate N, Sakhaee K</name></string-name></person-group>.<article-title> Pathophysiology of uric acid nephrolithiasis.</article-title><source> Endocrinology and Metabolism Clinics</source>. <year>2002</year>; <volume>31</volume>: <fpage>895</fpage>&#x2013;<lpage>914</lpage>.</mixed-citation></ref>
<ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Gambaro G, Trinchieri A</name></string-name></person-group>.<article-title> Recent advances in managing and understanding nephrolithiasis/nephrocalcinosis.</article-title><source> F1000Research</source>. <year>2016</year>; <volume>5</volume>: <page> F1000 Faculty Rev-695</page>.</mixed-citation></ref>
<ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sohgaura A, Bigoniya P</name></string-name></person-group>.<article-title> A review on epidemiology and etiology of renal stone.</article-title><source> American Journal of Drug Discovery and Development</source>. <year>2017</year>; <volume>7</volume>: <fpage>54</fpage>&#x2013;<lpage>62</lpage>.</mixed-citation></ref>
<ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Eisner BH, Goldfarb DS, Pareek G</name></string-name></person-group>.<article-title> Pharmacologic treatment of kidney stone disease.</article-title><source> Urologic Clinics</source>. <year>2013</year>; <volume>40</volume>: <fpage>21</fpage>&#x2013;<lpage>30</lpage>.</mixed-citation></ref>
<ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Evan AP, Worcester EM, Coe FL, Williams J, Lingeman JE</name></string-name></person-group>.<article-title> Mechanisms of human kidney stone formation.</article-title><source> Urolithiasis</source>. <year>2015</year>; <volume>43</volume>: <fpage>19</fpage>&#x2013;<lpage>32</lpage>.</mixed-citation></ref>
<ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Mittal A, Tandon S, Singla SK, Tandon C</name></string-name></person-group>.<article-title> <italic>In vitro</italic> inhibition of calcium oxalate crystallization and crystal adherence to renal tubular epithelial cells by Terminalia arjuna.</article-title><source> Urolithiasis</source>. <year>2016</year>; <volume>44</volume>: <fpage>117</fpage>&#x2013;<lpage>125</lpage>.</mixed-citation></ref>
<ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Siener R</name></string-name></person-group>.<article-title> Nutrition and kidney stone disease.</article-title><source> Nutrients</source>. <year>2021</year>; <volume>13</volume>: <page>1917</page>.</mixed-citation></ref>
<ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Alanazi NF, Alanazi MA, Alanazi BA, Alsaleh AK, Alomayri MI, Alanazi AT</name></string-name></person-group>, <italic>et al</italic>.<article-title> Renal colic disease: overview, management, and prevention.</article-title><source> Journal of Biochemical Technology</source>. <year>2020</year>; <volume>11</volume>: <fpage>85</fpage>&#x2013;<lpage>88</lpage>.</mixed-citation></ref>
<ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Dursun M, Otunctemur A, Ozbek E</name></string-name></person-group>.<article-title> Kidney stones and ceftriaxone.</article-title><source> EMJ Urology</source>. <year>2015</year>; <volume>3</volume>: <fpage>68</fpage>&#x2013;<lpage>74</lpage>.</mixed-citation></ref>
<ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Naik RV, Patil SB</name></string-name></person-group>.<article-title> A review on pathogenesis, diagnosis, and management of urolithiasis.</article-title><source> Journal of Pharma Insights and Research</source>. <year>2025</year>; <volume>3</volume>: <fpage>75</fpage>&#x2013;<lpage>85</lpage>.</mixed-citation></ref>
<ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Anlauf M, Hein L, Hense HW, Köbberling J, Lasek R, Leidl R</name></string-name></person-group>, <italic>et al</italic>.<article-title> Complementary and alternative drug therapy versus science-oriented medicine.</article-title><source> German Medical Science</source>. <year>2015</year>; <volume>13</volume>: <page>Doc05</page>.</mixed-citation></ref>
<ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ebert N, Bevc S, Bökenkamp A, Gaillard F, Hornum M, Jager KJ</name></string-name></person-group>, <italic>et al</italic>.<article-title> Assessment of kidney function: clinical indications for measured GFR.</article-title><source> Clinical Kidney Journal</source>. <year>2021</year>; <volume>14</volume>: <fpage>1861</fpage>&#x2013;<lpage>1870</lpage>.</mixed-citation></ref>
<ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Stepanova N</name></string-name></person-group>.<article-title> Balancing stone prevention and kidney function: a therapeutic dilemma.</article-title><source> Journal of Clinical Medicne</source>. <year>2025</year>; <volume>14</volume>: <page>3678</page>.</mixed-citation></ref>
<ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ibis F, Yu TW, Penha FM, Ganguly D, Nuhu MA, Van Der Heijden AE</name></string-name></person-group>, <italic>et al</italic>.<article-title> Nucleation kinetics of calcium oxalate monohydrate as a function of pH, magnesium, and osteopontin concentration quantified with droplet microfluidics.</article-title><source> Biomicrofluidics</source>. <year>2021</year>; <volume>15</volume>: <page>64103</page>.</mixed-citation></ref>
<ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sobirov I, Erniyozov B, Aliqulov J</name></string-name></person-group>.<article-title> Urolithiasis pathogenesis risk factors and modern treatment approaches.</article-title><source> Frontiers of Global Science</source>. <year>2025</year>; <volume>3</volume>: <fpage>53</fpage>&#x2013;<lpage>58</lpage>.</mixed-citation></ref>
<ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sun XY, Chen JY, Rao CY, Ouyang JM</name></string-name></person-group>.<article-title> Size-dependent cytotoxicity of hydroxyapatite crystals on renal epithelial cells.</article-title><source> International Journal of Nanomedicine</source>. <year>2020</year>; <volume>15</volume>: <fpage>5043</fpage>&#x2013;<lpage>5060</lpage>.</mixed-citation></ref>
<ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Kulsoom, Ahmad S, Urwa, Khan IA, Awais, Pricope R</name></string-name></person-group>, <italic>et al</italic>.<article-title> Associations between clinical, biochemical, and nutritional factors in kidney stone formation and recurrence.</article-title><source> Urolithiasis</source>. <year>2025</year>; <volume>53</volume>: <page>112</page>.</mixed-citation></ref>
<ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Saifullah F, Saeed MA</name></string-name></person-group>.<article-title> Kidney stones: pathophysiology, cutting-edge treatments, and emerging concerns.</article-title><source> Currents in Pharmaceutical Research</source>. <year>2025</year>; <volume>2</volume>: <fpage>89</fpage>&#x2013;<lpage>118</lpage>.</mixed-citation></ref>
<ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Shafi H, Moazzami B, Pourghasem M, Kasaeian A</name></string-name></person-group>.<article-title> An overview of treatment options for urinary stones.</article-title><source> Caspian Journal of Internal Medicine</source>. <year>2016</year>; <volume>7</volume>: <fpage>1</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Damian DJ, McNamee R, Carr M</name></string-name></person-group>.<article-title> Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial.</article-title><source> BMC Cardiovascular Disorders</source>. <year>2016</year>; <volume>16</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Huang R, Zhang YH, Huang H, Yang HS</name></string-name></person-group>.<article-title> The oxalate content of oolong tea and its relationship with soaking times.</article-title><source> Urolithiasis</source>. <year>2016</year>; <volume>44</volume>: <fpage>477</fpage>&#x2013;<lpage>478</lpage>.</mixed-citation></ref>
<ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van’t Hoff W</name></string-name></person-group>, <italic>et al</italic>.<article-title> A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.</article-title><source> Pediatric Nephrology</source>. <year>2017</year>; <volume>32</volume>: <fpage>781</fpage>&#x2013;<lpage>790</lpage>.</mixed-citation></ref>
<ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sakhaee K</name></string-name></person-group>.<article-title> Medical measures for secondary prevention of urolithiasis.</article-title><source> European Urology Focus</source>. <year>2017</year>; <volume>3</volume>: <fpage>10</fpage>&#x2013;<lpage>12</lpage>.</mixed-citation></ref>
<ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Morgan MS, Pearle MS</name></string-name></person-group>.<article-title> Medical management of renal stones.</article-title><source> The BMJ</source>. <year>2016</year>; <volume>352</volume>: <page>i52</page>.</mixed-citation></ref>
<ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R</name></string-name></person-group>.<article-title> Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis.</article-title><source> The American Journal of Clinical Nutrition</source>. <year>2016</year>; <volume>104</volume>: <fpage>1039</fpage>&#x2013;<lpage>1051</lpage>.</mixed-citation></ref>
<ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ceylan K, Topal C, Erkoc R, Sayarlioglu H, Can S, Yilmaz Y</name></string-name></person-group>, <italic>et al</italic>.<article-title> Effect of indapamide on urinary calcium excretion in patients with and without urinary stone disease.</article-title><source> Annals of Pharmacotherapy</source>. <year>2005</year>; <volume>39</volume>: <fpage>1034</fpage>&#x2013;<lpage>1038</lpage>.</mixed-citation></ref>
<ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Tavasoli S, Alebouyeh M, Naji M, Shakiba majd G, Shabani Nashtaei M, Broumandnia N</name></string-name></person-group>, <italic>et al</italic>.<article-title> Association of intestinal oxalate‐degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.</article-title><source> BJU International</source>. <year>2020</year>; <volume>125</volume>: <fpage>133</fpage>&#x2013;<lpage>143</lpage>.</mixed-citation></ref>
<ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Spivacow FR, Del Valle EE, Lores E, Rey PG</name></string-name></person-group>.<article-title> Kidney stones: composition, frequency and relation to metabolic diagnosis.</article-title><source> Medicina</source>. <year>2016</year>; <volume>76</volume>: <fpage>343</fpage>&#x2013;<lpage>348</lpage>.</mixed-citation></ref>
<ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Astroza GM, Neisius A, Tsivian M, Preminger GM, Lipkin ME</name></string-name></person-group>.<article-title> Treatment response in patients with stones, and low urinary pH and hypocitraturia stratified by body mass index.</article-title><source> The Journal of Urology</source>. <year>2016</year>; <volume>195</volume>: <fpage>653</fpage>&#x2013;<lpage>657</lpage>.</mixed-citation></ref>
<ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Rizwan B</name></string-name></person-group>.<article-title> Health benefits of asparagus.</article-title><source> Pakistan Journal of Health Sciences</source>. <year>2020</year>; <volume>1</volume>: <fpage>14</fpage>&#x2013;<lpage>16</lpage>.</mixed-citation></ref>
<ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Khan F, Haider MF, Singh MK, Sharma P, Kumar T, Neda EN</name></string-name></person-group>.<article-title> A comprehensive review on kidney stones, its diagnosis and treatment with allopathic and ayurvedic medicines.</article-title><source> Urology &amp; Nephrology Open Access Journal</source>. <year>2019</year>; <volume>7</volume>: <fpage>69</fpage>&#x2013;<lpage>74</lpage>.</mixed-citation></ref>
<ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sachdeva S, Kaur J, Mehta S, Saharan R, Nain P</name></string-name></person-group>.<article-title> Formulation of ayurvedic medicines and extracts of medicinal plants as an alternative therapeutic treatment option for nephrolithiasis.</article-title><source> World Journal of Traditional Chinese Medicine</source>. <year>2023</year>; <volume>9</volume>: <fpage>278</fpage>&#x2013;<lpage>283</lpage>.</mixed-citation></ref>
<ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Azam F, Munier S, Batoo M, Ahmad B, Abbas G</name></string-name></person-group>.<article-title> A review on advancements in ethnomedicine and phytochemistry of Tribulus terrestris—a plant with multiple health benefits.</article-title><source> International Journal of Biosciences</source>. <year>2019</year>; <volume>14</volume>: <fpage>21</fpage>&#x2013;<lpage>37</lpage>.</mixed-citation></ref>
<ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Narendra K, Swathi J, Sowjanya KM, Satya AK</name></string-name></person-group>.<article-title> Phyllanthus niruri: a review on its ethno botanical, phytochemical and pharmacological profile.</article-title><source> Journal of Pharmacy Research</source>. <year>2012</year>; <volume>5</volume>: <fpage>4681</fpage>&#x2013;<lpage>4691</lpage>.</mixed-citation></ref>
<ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Niu Z, Duan Z, He W, Chen T, Tang H, Du S</name></string-name></person-group>, <italic>et al</italic>.<article-title> Kidney function decline mediates the adverse effects of per- and poly-fluoroalkyl substances (PFAS) on uric acid levels and hyperuricemia risk.</article-title><source> Journal of Hazardous Materials</source>. <year>2024</year>; <volume>471</volume>: <page>134312</page>.</mixed-citation></ref>
<ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Tolsarwad GS, Biradar MM, Shinde SA</name></string-name></person-group>.<article-title> Potential pharmacognostic interventions of Crataeva nurvala: a pharmacological views.</article-title><source> Innovations in Pharmaceuticals and Pharmacotherapy</source>. <year>2020</year>; <volume>8</volume>: <fpage>66</fpage>&#x2013;<lpage>73</lpage>.</mixed-citation></ref>
<ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Wang X, Wang Q</name></string-name></person-group>.<article-title> Current dietary and medical prevention of renal calcium oxalate stones.</article-title><source> International Journal of General Medicine</source>. <year>2024</year>; <volume>17</volume>: <fpage>1635</fpage>&#x2013;<lpage>1649</lpage>.</mixed-citation></ref>
<ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Santarosa BP, Ferreira DO, Surian SR, Tremori TM, Hooper HB, Silva PD</name></string-name></person-group>, <italic>et al</italic>.<article-title> Clinical and anatomopathological study of urolithiasis in feedlot lambs subjected to diets with different phosphorus concentrations.</article-title><source> Ciência Animal Brasileira</source>. <year>2021</year>; <volume>22</volume>: <page>e67849</page>.</mixed-citation></ref>
<ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sharma S, Sharma N, Gupta PC, Verma R, Yadav V</name></string-name></person-group>.<article-title> An update on kidney stones: types, mechanism and treatment approaches.</article-title><source> Research Journal of Pharmacognosy and Phytochemistry</source>. <year>2023</year>; <volume>15</volume>: <fpage>53</fpage>&#x2013;<lpage>62</lpage>.</mixed-citation></ref>
<ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Abdulrida JJ, Kadhim HY</name></string-name></person-group>.<article-title> Assessment of patient’s knowledge about avoidance of recurrent urolithiasis.</article-title><source> Kufa Journal for Nursing Sciences</source>. <year>2015</year>; <volume>5</volume>: <fpage>1</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Knight J, Nigam Y, Jones A</name></string-name></person-group>.<article-title> Effects of bedrest 4: renal, reproductive and immune systems.</article-title><source> Nursing Times</source>. <year>2019</year>; <volume>115</volume>: <fpage>51</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Bosio A, Alessandria E, Dalmasso E, Agosti S, Vitiello F, Vercelli E</name></string-name></person-group>, <italic>et al</italic>.<article-title> Flexible ureterorenoscopy versus shockwave lithotripsy for kidney stones ≤2 cm: a randomized controlled trial.</article-title><source> European Urology Focus</source>. <year>2022</year>; <volume>8</volume>: <fpage>1816</fpage>&#x2013;<lpage>1822</lpage>.</mixed-citation></ref>
<ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>El-Shaer W, Abdel-Lateef S, Torky A, Elshaer A</name></string-name></person-group>.<article-title> Complete ultrasound-guided percutaneous nephrolithotomy in prone and supine positions: a randomized controlled study.</article-title><source> Urology</source>. <year>2019</year>; <volume>128</volume>: <fpage>31</fpage>&#x2013;<lpage>37</lpage>.</mixed-citation></ref>
<ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ding H, Ning Z, Dai Y, Shang P, Yang L</name></string-name></person-group>.<article-title> The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis.</article-title><source> Renal Failure</source>. <year>2016</year>; <volume>38</volume>: <fpage>1311</fpage>&#x2013;<lpage>1319</lpage>.</mixed-citation></ref>
<ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Elbaset MA, Taha DE, Anas M, Abouelkheir RT, Edwan M, Abdullateef M</name></string-name></person-group>, <italic>et al</italic>.<article-title> Optimization of shockwave lithotripsy use for single medium sized hard renal stone with stone density ≥1000 HU.  A prospective study.</article-title><source> World Journal of Urology</source>. <year>2022</year>; <volume>40</volume>: <fpage>243</fpage>&#x2013;<lpage>250</lpage>.</mixed-citation></ref>
<ref id="ref59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Canvasser NE, Rivera M, Bechis SK, Ingimarsson J, Knoedler J, Stern K</name></string-name></person-group>, <italic>et al</italic>.<article-title> Over-the-counter alkali agents to raise urine pH and citrate excretion: a prospective crossover study in healthy adults.</article-title><source> Urology</source>. <year>2022</year>; <volume>168</volume>: <fpage>72</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ripa F, Tokas T, Griffin S, Ferretti S, Tur AB, Somani BK</name></string-name></person-group>.<article-title> Role of pediatric ureteral access sheath and outcomes related to flexible ureteroscopy and laser stone fragmentation: a systematic review of literature.</article-title><source> European Urology Open Science</source>. <year>2022</year>; <volume>45</volume>: <fpage>90</fpage>&#x2013;<lpage>98</lpage>.</mixed-citation></ref>
<ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Chamorro MM, Collado SA, Márquez D</name></string-name></person-group>.<article-title> Effectiveness of using Renalof® in the elimination of kidney stones under 10 mm located in the renal-ureteral tract.</article-title><source> Open Journal of Nephrology</source>. <year>2021</year>; <volume>11</volume>: <fpage>78</fpage>&#x2013;<lpage>92</lpage>.</mixed-citation></ref>
<ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Saxena A, Sharma RK</name></string-name></person-group>.<article-title> Nutritional aspect of nephrolithiasis.</article-title><source> Indian Journal of Urology</source>. <year>2010</year>; <volume>26</volume>: <fpage>523</fpage>&#x2013;<lpage>530</lpage>.</mixed-citation></ref>
<ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Dogliotti E, Vezzoli G, Nouvenne A, Meschi T, Terranegra A, Mingione A</name></string-name></person-group>, <italic>et al</italic>.<article-title> Nutrition in calcium nephrolithiasis.</article-title><source> Journal of Translational Medicine</source>. <year>2013</year>; <volume>11</volume>: <page>109</page>.</mixed-citation></ref>
<ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Han H, Segal AM, Seifter JL, Dwyer JT</name></string-name></person-group>.<article-title> Nutritional management of kidney stones (nephrolithiasis).</article-title><source> Clinical Nutrition Research</source>. <year>2015</year>; <volume>4</volume>: <fpage>137</fpage>&#x2013;<lpage>152</lpage>.</mixed-citation></ref>
<ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>de Oliveira LM, Hauschild DB, Leite CD, Baptista DR, Carvalho M</name></string-name></person-group>.<article-title> Adequate dietary intake and nutritional status in patients with nephrolithiasis: new targets and objectives.</article-title><source> Journal of Renal Nutrition</source>. <year>2014</year>; <volume>24</volume>: <fpage>417</fpage>&#x2013;<lpage>422</lpage>.</mixed-citation></ref>
<ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Grases F, Costa-Bauza A, Prieto RM</name></string-name></person-group>.<article-title> Renal lithiasis and nutrition.</article-title><source> Nutrition Journal</source>. <year>2006</year>; <volume>5</volume>: <page>23</page>.</mixed-citation></ref>
<ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Meyers AM, Naicker S</name></string-name></person-group>.<article-title> Nephrolithiasis (part 1): epidemiology, causes and pathogenesis of recurrent nephrolithiasis.</article-title><source> South African Medical Journal</source>. <year>2021</year>; <volume>111</volume>: <fpage>930</fpage>&#x2013;<lpage>933</lpage>.</mixed-citation></ref>
<ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Wigner P, Grębowski R, Bijak M, Szemraj J, Saluk-Bijak J</name></string-name></person-group>.<article-title> The molecular aspect of nephrolithiasis development.</article-title><source> Cells</source>. <year>2021</year>; <volume>10</volume>: <page>1926</page>.</mixed-citation></ref>
<ref id="ref69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Nouvenne A, Meschi T, Guerra A, Allegri F, Prati B, Borghi L</name></string-name></person-group>.<article-title> Dietary treatment of nephrolithiasis.</article-title><source> Clinical Cases in Mineral and Bone Metabolism</source>. <year>2008</year>; <volume>5</volume>: <fpage>135</fpage>&#x2013;<lpage>141</lpage>.</mixed-citation></ref>
<ref id="ref70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Lightfoot CJ, Wilkinson TJ, Smith AC</name></string-name></person-group>.<article-title> Non-pharmacological management of chronic kidney disease.</article-title><source> Medicine</source>. <year>2023</year>; <volume>51</volume>: <fpage>170</fpage>&#x2013;<lpage>175</lpage>.</mixed-citation></ref>
<ref id="ref71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ticinesi A, Nouvenne A, Chiussi G, Castaldo G, Guerra A, Meschi T</name></string-name></person-group>.<article-title> Calcium oxalate nephrolithiasis and gut microbiota: not just a gut-kidney axis.  A nutritional perspective.</article-title><source> Nutrients</source>. <year>2020</year>; <volume>12</volume>: <page>548</page>.</mixed-citation></ref>
<ref id="ref72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>D’Ambrosio V, Ferraro PM, Lombardi G, Friso S, Gambaro G</name></string-name></person-group>.<article-title> Unravelling the complex relationship between diet and nephrolithiasis: the role of nutrigenomics and nutrigenetics.</article-title><source> Nutrients</source>. <year>2022</year>; <volume>14</volume>: <page>4961</page>.</mixed-citation></ref>
<ref id="ref73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Worcester EM, Coe FL</name></string-name></person-group>.<article-title> Nephrolithiasis.</article-title><source> Primary Care: Clinics in Office Practice</source>. <year>2008</year>; <volume>35</volume>: <fpage>369</fpage>&#x2013;<lpage>391</lpage>.</mixed-citation></ref>
<ref id="ref74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Oliveira MC, Goes CR</name></string-name></person-group>.<article-title> Mini-review: dietary influency and nutritional treatment in nephrolithiasis.</article-title><source> Nutrire</source>. <year>2022</year>; <volume>47</volume>: <page>14</page>.</mixed-citation></ref>
<ref id="ref75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Soldati L, Bertoli S, Terranegra A, Brasacchio C, Mingione A, Dogliotti E</name></string-name></person-group>, <italic>et al</italic>.<article-title> Relevance of Mediterranean diet and glucose metabolism for nephrolithiasis in obese subjects.</article-title><source> Journal of Translational Medicine</source>. <year>2014</year>; <volume>12</volume>: <page>34</page>.</mixed-citation></ref>
<ref id="ref76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Wasserstein AG</name></string-name></person-group>.<article-title> Epidemiology and natural history of nephrolithiasis.</article-title><source> Clinical Reviews in Bone and Mineral Metabolism</source>. <year>2011</year>; <volume>9</volume>: <fpage>165</fpage>&#x2013;<lpage>180</lpage>.</mixed-citation></ref>
<ref id="ref77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Cupisti A, D’Alessandro C, Samoni S, Meola M, Egidi MF</name></string-name></person-group>.<article-title> Nephrolithiasis and hypertension: possible links and clinical implications.</article-title><source> Journal of Nephrology</source>. <year>2014</year>; <volume>27</volume>: <fpage>477</fpage>&#x2013;<lpage>482</lpage>.</mixed-citation></ref>
<ref id="ref78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Meschi T, Nouvenne A, Ticinesi A, Prati B, Guerra A, Allegri F</name></string-name></person-group>, <italic>et al</italic>.<article-title> Dietary habits in women with recurrent idiopathic calcium nephrolithiasis.</article-title><source> Journal of Translational Medicine</source>. <year>2012</year>; <volume>10</volume>: <page>63</page>.</mixed-citation></ref>
<ref id="ref79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Santos FM, Peres AK, Mandotti MR, Peres LA</name></string-name></person-group>.<article-title> Metabolic investigation in patients with nephrolithiasis.</article-title><source> Einstein</source>. <year>2017</year>; <volume>15</volume>: <fpage>452</fpage>&#x2013;<lpage>456</lpage>.</mixed-citation></ref>
<ref id="ref80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Gambaro G, Reis-Santos JM, Rao N</name></string-name></person-group>.<article-title> Nephrolithiasis: why doesn’t our “learning” progress? </article-title><source>European Urology</source>. <year>2004</year>; <volume>45</volume>: <fpage>547</fpage>&#x2013;<lpage>556</lpage>.</mixed-citation></ref>
<ref id="ref81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>D’Ambrosio V, Moochhala S, Unwin RJ, Ferraro PM</name></string-name></person-group>.<article-title> Why is diagnosis, investigation, and improved management of kidney stone disease important? Non-pharmacological and pharmacological treatments for nephrolithiasis.</article-title><source> Expert Review of Clinical Pharmacology</source>. <year>2022</year>; <volume>15</volume>: <fpage>407</fpage>&#x2013;<lpage>414</lpage>.</mixed-citation></ref>
<ref id="ref82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Tiselius HG</name></string-name></person-group>.<article-title> Medical evaluation of nephrolithiasis.</article-title><source> Endocrinology and Metabolism Clinics</source>. <year>2002</year>; <volume>31</volume>: <fpage>1031</fpage>&#x2013;<lpage>1050</lpage>.</mixed-citation></ref>
<ref id="ref83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Zhao A, Dai M, Chen YJ, Chang HE, Liu AP, Wang PY</name></string-name></person-group>.<article-title> Risk factors associated with nephrolithiasis: a case-control study in China.</article-title><source> Asia Pacific Journal of Public Health</source>. <year>2015</year>; <volume>27</volume>: <fpage> NP414</fpage>&#x2013;<lpage>NP424</lpage>.</mixed-citation></ref>
<ref id="ref84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Churchill DN</name></string-name></person-group>.<article-title> Urolithiasis-nutritional aspects.</article-title><source> Nutrition Research</source>. <year>1983</year>; <volume>3</volume>: <fpage>761</fpage>&#x2013;<lpage>771</lpage>.</mixed-citation></ref>
<ref id="ref85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Hesse A, Siener R</name></string-name></person-group>.<article-title> Current aspects of epidemiology and nutrition in urinary stone disease.</article-title><source> World Journal of Urology</source>. <year>1997</year>; <volume>15</volume>: <fpage>165</fpage>&#x2013;<lpage>171</lpage>.</mixed-citation></ref>
<ref id="ref86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Remer T, Kalotai N, Amini AM, Lehmann A, Schmidt A, Bischoff-Ferrari HA</name></string-name></person-group>, <italic>et al</italic>.<article-title> Protein intake and risk of urolithiasis and kidney diseases: an umbrella review of systematic reviews for the evidence-based guideline of the German Nutrition Society.</article-title><source> European Journal of Nutrition</source>. <year>2023</year>; <volume>62</volume>: <fpage>1957</fpage>&#x2013;<lpage>1975</lpage>.</mixed-citation></ref>
<ref id="ref87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Marra G, Taroni F, Berrettini A, Montanari E, Manzoni G, Montini G</name></string-name></person-group>.<article-title> Pediatric nephrolithiasis: a systematic approach from diagnosis to treatment.</article-title><source> Journal of Nephrology</source>. <year>2019</year>; <volume>32</volume>: <fpage>199</fpage>&#x2013;<lpage>210</lpage>.</mixed-citation></ref>
<ref id="ref88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Liu YT, Yang PY, Yang YW, Sun HY, Lin IC</name></string-name></person-group>.<article-title> The association of nephrolithiasis with metabolic syndrome and its components: a cross-sectional analysis.</article-title><source> Therapeutics and Clinical Risk Management</source>. <year>2017</year>; <volume>13</volume>: <fpage>41</fpage>&#x2013;<lpage>48</lpage>.</mixed-citation></ref>
<ref id="ref89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ciongradi CI, Filip F, Sârbu I, Iliescu Halițchi CO, Munteanu V, Candussi IL</name></string-name></person-group>.<article-title> The impact of water and other fluids on pediatric nephrolithiasis.</article-title><source> Nutrients</source>. <year>2022</year>; <volume>14</volume>: <page>4161</page>.</mixed-citation></ref>
<ref id="ref90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Nouvenne A, Ticinesi A, Meschi T</name></string-name></person-group>.<article-title> Nephrolithiasis and gastrointestinal tract diseases: can diet intervention help? </article-title><source>Practical Gastroenterology</source>. <year>2013</year>; <volume>116</volume>: <fpage>27</fpage>&#x2013;<lpage>35</lpage>.</mixed-citation></ref>
<ref id="ref91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Van den Eynde J, Delpire B, Jacquemyn X, Pardi I, Rotbi H, Gewillig M</name></string-name></person-group>, <italic>et al</italic>.<article-title> Risk factors for acute kidney injury after pediatric cardiac surgery: a meta-analysis.</article-title><source> Pediatr Nephrol</source>. <year>2022</year>; <volume>37</volume>: <fpage>509</fpage>&#x2013;<lpage>519</lpage>.</mixed-citation></ref>
<ref id="ref92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Attanasio M</name></string-name></person-group>.<article-title> The genetic components of idiopathic nephrolithiasis.</article-title><source> Pediatric Nephrology</source>. <year>2011</year>; <volume>26</volume>: <fpage>337</fpage>&#x2013;<lpage>346</lpage>.</mixed-citation></ref>
<ref id="ref93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Allam EA</name></string-name></person-group>.<article-title> Urolithiasis unveiled: pathophysiology, stone dynamics, types, and inhibitory mechanisms: a review.</article-title><source> African Journal of Urology</source>. <year>2024</year>; <volume>30</volume>: <page>34</page>.</mixed-citation></ref>
<ref id="ref94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ziemba JB, Matlaga BR</name></string-name></person-group>.<article-title> Epidemiology and economics of nephrolithiasis.</article-title><source> Investigative and Clinical Urology</source>. <year>2017</year>; <volume>58</volume>: <fpage>299</fpage>&#x2013;<lpage>306</lpage>.</mixed-citation></ref>
<ref id="ref95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Wal P, Kaushal S, Dwivedi J, Patel P, Sachan P, Srivastava P</name></string-name></person-group>.<article-title> Multifunctional roles and phytopharmacological potential of ursolic acid: an invaluable natural nutraceutical agent.</article-title><source> Russian Journal of Bioorganic Chemistry</source>. <year>2025</year>; <volume>51</volume>: <fpage>1</fpage>&#x2013;<lpage>34</lpage>.</mixed-citation></ref>
<ref id="ref96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Afsar B, Kiremit MC, Sag AA, Tarim K, Acar O, Esen T</name></string-name></person-group>, <italic>et al</italic>.<article-title> The role of sodium intake in nephrolithiasis: epidemiology, pathogenesis, and future directions.</article-title><source> European Journal of Internal Medicine</source>. <year>2016</year>; <volume>35</volume>: <fpage>16</fpage>&#x2013;<lpage>19</lpage>.</mixed-citation></ref>
<ref id="ref97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Soroushzadeh SM, Zareiyan A, Rezaeizadeh H, Karimi M, Arezaei H, Vaghasloo MA</name></string-name></person-group>.<article-title> Nutritional viscosity management for renal stones (nephrolithiasis) prevention according to Avicenna’s canon of medicine.</article-title><source> Journal of Pharmaceutical Research International</source>. <year>2019</year>; <volume>31</volume>: <fpage>1</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="ref98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Tamborino F, Cicchetti R, Mascitti M, Litterio G, Orsini A, Ferretti S</name></string-name></person-group>, <italic>et al</italic>.<article-title> Pathophysiology and main molecular mechanisms of urinary stone formation and recurrence.</article-title><source> International Journal of Molecular Sciences</source>. <year>2024</year>; <volume>25</volume>: <page>3075</page>.</mixed-citation></ref>
<ref id="ref99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Meyers AM, Naicker S</name></string-name></person-group>.<article-title> Nephrolithiasis (part 2): diagnosis, management and prevention of recurrent nephrolithiasis.</article-title><source> South African Medical Journal</source>. <year>2021</year>; <volume>111</volume>: <fpage>1042</fpage>&#x2013;<lpage>1045</lpage>.</mixed-citation></ref>
<ref id="ref100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Hess B, Hasler-Strub U, Ackermann D, Jaeger P</name></string-name></person-group>.<article-title> Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis.</article-title><source> Nephrology, Dialysis, Transplantation</source>. <year>1997</year>; <volume>12</volume>: <fpage>1362</fpage>&#x2013;<lpage>1368</lpage>.</mixed-citation></ref>
<ref id="ref101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Pedro RN, Aslam AU, Bello JO, Bhatti KH, Philipraj J, Sissoko I</name></string-name></person-group>, <italic>et al</italic>.<article-title> Nutrients, vitamins, probiotics and herbal products: an update of their role in urolithogenesis.</article-title><source> Urolithiasis</source>. <year>2020</year>; <volume>48</volume>: <fpage>285</fpage>&#x2013;<lpage>301</lpage>.</mixed-citation></ref>
<ref id="ref102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Abou Chakra M, Dellis AE, Papatsoris AG, Moussa M</name></string-name></person-group>.<article-title> Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium.</article-title><source> Expert Opinion on Pharmacotherapy</source>. <year>2020</year>; <volume>21</volume>: <fpage>85</fpage>&#x2013;<lpage>96</lpage>.</mixed-citation></ref>
<ref id="ref103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Hefer M, Huskic IM, Petrovic A, Raguz-Lucic N, Kizivat T, Gjoni D</name></string-name></person-group>, <italic>et al</italic>.<article-title> A mechanistic insight into beneficial effects of polyphenols in the prevention and treatment of nephrolithiasis: evidence from recent <italic>in vitro</italic> studies.</article-title><source> Crystals</source>. <year>2023</year>; <volume>13</volume>: <page>1070</page>.</mixed-citation></ref>
<ref id="ref104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Nazarian R, Lin N, Thaker S, Yang R, Wong GC, Scotland KB</name></string-name></person-group>.<article-title> What causes calcium oxalate kidney stones to form? An update on recent advances.</article-title><source> Uro</source>. <year>2025</year>; <volume>5</volume>: <page>6</page>.</mixed-citation></ref>
<ref id="ref105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Injeyan M, Bidault V, Bacchetta J, Bertholet-Thomas A</name></string-name></person-group>.<article-title> Hydration and nephrolithiasis in pediatric populations: specificities and current recommendations.</article-title><source> Nutrients</source>. <year>2023</year>; <volume>15</volume>: <page>728</page>.</mixed-citation></ref>
<ref id="ref106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Roberson D, Sperling C, Shah A, Ziemba J</name></string-name></person-group>.<article-title> Economic considerations in the management of nephrolithiasis.</article-title><source> Current Urology Reports</source>. <year>2020</year>; <volume>21</volume>: <page>18</page>.</mixed-citation></ref>
<ref id="ref107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ticinesi A, Nouvenne A, Borghi L, Meschi T</name></string-name></person-group>.<article-title> Water and other fluids in nephrolithiasis: state of the art and future challenges.</article-title><source> Critical Reviews in Food Science and Nutrition</source>. <year>2017</year>; <volume>57</volume>: <fpage>963</fpage>&#x2013;<lpage>974</lpage>.</mixed-citation></ref>
<ref id="ref108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Abraham PA, Smith CL</name></string-name></person-group>.<article-title> Medical evaluation and management of calcium nephrolithiasis.</article-title><source> Medical Clinics of North America</source>. <year>1984</year>; <volume>68</volume>: <fpage>281</fpage>&#x2013;<lpage>299</lpage>.</mixed-citation></ref>
<ref id="ref109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M</name></string-name></person-group>.<article-title> Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review.</article-title><source> American Journal of Kidney Diseases</source>. <year>2022</year>; <volume>79</volume>: <fpage>717</fpage>&#x2013;<lpage>727</lpage>.</mixed-citation></ref>
<ref id="ref110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Cameron MA, Pak CY</name></string-name></person-group>.<article-title> Approach to the patient with the first episode of nephrolithiasis.</article-title><source> Clinical Reviews in Bone and Mineral Metabolism</source>. <year>2004</year>; <volume>2</volume>: <fpage>265</fpage>&#x2013;<lpage>278</lpage>.</mixed-citation></ref>
<ref id="ref111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Rendina D, De Filippo G, Iannuzzo G, Abate V, Strazzullo P, Falchetti A</name></string-name></person-group>.<article-title> Idiopathic osteoporosis and nephrolithiasis: two sides of the same coin? </article-title><source>International Journal of Molecular Sciences</source>. <year>2020</year>; <volume>21</volume>: <page>8183</page>.</mixed-citation></ref>
<ref id="ref112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Domrongkitchaiporn S, Sopassathit W, Stitchantrakul W, Prapaipanich S, Ingsathit A, Rajatanavin R</name></string-name></person-group>.<article-title> Schedule of taking calcium supplement and the risk of nephrolithiasis.</article-title><source> Kidney International</source>. <year>2004</year>; <volume>65</volume>: <fpage>1835</fpage>&#x2013;<lpage>1841</lpage>.</mixed-citation></ref>
<ref id="ref113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Alexander RT, Fuster DG, Dimke H</name></string-name></person-group>.<article-title> Mechanisms underlying calcium nephrolithiasis.</article-title><source> Annual Review of Physiology</source>. <year>2022</year>; <volume>84</volume>: <fpage>559</fpage>&#x2013;<lpage>583</lpage>.</mixed-citation></ref>
<ref id="ref114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Taylor EN, Curhan GC</name></string-name></person-group>.<article-title> Role of nutrition in the formation of calcium-containing kidney stones.</article-title><source> Nephron Physiology</source>. <year>2004</year>; <volume>98</volume>: <fpage> p55</fpage>&#x2013;<lpage>p63</lpage>.</mixed-citation></ref>
<ref id="ref115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Hess B</name></string-name></person-group>.<article-title> Low calcium diet in hypercalciuric calcium nephrolithiasis: first do no harm.</article-title><source> Scanning Microscopy</source>. <year>1996</year>; <volume>10</volume>: <fpage>547</fpage>&#x2013;<lpage>554</lpage>.</mixed-citation></ref>
<ref id="ref116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Zielinski P, Krupinska J, Wrobel G</name></string-name></person-group>.<article-title> The impact of chemical compounds contained in a diet on the development and prevention of urolithiasis.</article-title><source> Journal of Elementology</source>. <year>2021</year>; <volume>26</volume>: <fpage>163</fpage>&#x2013;<lpage>179</lpage>.</mixed-citation></ref>
<ref id="ref117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Batanjac J</name></string-name></person-group>.<article-title> Nutritional aspects in oxalic urolithiasis.</article-title><source> The Scientific Journal Facta Universitatis, Series: Medicine and Biology</source>. <year>2000</year>; <volume>7</volume>: <fpage>49</fpage>&#x2013;<lpage>51</lpage>.</mixed-citation></ref>
<ref id="ref118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Shin S, Srivastava A, Alli NA, Bandyopadhyay BC</name></string-name></person-group>.<article-title> Confounding risk factors and preventative measures driving nephrolithiasis global makeup.</article-title><source> World Journal of Nephrology</source>. <year>2018</year>; <volume>7</volume>: <fpage>129</fpage>&#x2013;<lpage>142</lpage>.</mixed-citation></ref>
<ref id="ref119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>He R, Li P, Lang Y, Zhu B, Yang X, Li J</name></string-name></person-group>.<article-title> Associations of obesity, sarcopenia, and sarcopenic obesity with the risk of kidney stones in the US adult: results from NHANES 2011–2018.</article-title><source> Urolithiasis</source>. <year>2025</year>; <volume>53</volume>: <page>111</page>.</mixed-citation></ref>
<ref id="ref120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Rotily M, Léonetti F, Iovanna C, Berthezene P, Dupuy P, Vazi A</name></string-name></person-group>, <italic>et al</italic>.<article-title> Effects of low animal protein or high-fiber diets on urine composition in calcium nephrolithiasis.</article-title><source> Kidney International</source>. <year>2000</year>; <volume>57</volume>: <fpage>1115</fpage>&#x2013;<lpage>1123</lpage>.</mixed-citation></ref>
<ref id="ref121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Nouvenne A, Ticinesi A, Allegri F, Guerra A, Guida L, Morelli I</name></string-name></person-group>, <italic>et al</italic>.<article-title> Twenty-five years of idiopathic calcium nephrolithiasis: has anything changed? </article-title><source>Clinical Chemistry and Laboratory Medicine</source>. <year>2014</year>; <volume>52</volume>: <fpage>337</fpage>&#x2013;<lpage>344</lpage>.</mixed-citation></ref>
<ref id="ref122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Daudon M, Dessombz A, Frochot V, Letavernier E, Haymann JP, Jungers P</name></string-name></person-group>, <italic>et al</italic>.<article-title> Comprehensive morpho-constitutional analysis of urinary stones improves etiological diagnosis and therapeutic strategy of nephrolithiasis.</article-title><source> Comptes Rendus Chimie</source>. <year>2016</year>; <volume>19</volume>: <fpage>1470</fpage>&#x2013;<lpage>1491</lpage>.</mixed-citation></ref>
<ref id="ref123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Rodriguez Cuellar CI, Wang PZ, Freundlich M, Filler G</name></string-name></person-group>.<article-title> Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones.</article-title><source> Pediatric Nephrology</source>. <year>2020</year>; <volume>35</volume>: <fpage>383</fpage>&#x2013;<lpage>397</lpage>.</mixed-citation></ref>
<ref id="ref124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Dwivedi J, Sachan P, Wal P</name></string-name></person-group>.<article-title> A mechanistic approach on structural, analytical and pharmacological potential of Beta-sitosterol: a promising nutraceutical.</article-title><source> Current Nutrition &amp; Food Science</source>. <year>2024</year>; <volume>20</volume>: <fpage>932</fpage>&#x2013;<lpage>951</lpage>.</mixed-citation></ref>
<ref id="ref125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ahmed M, Zareen H, Shaharyar M</name></string-name></person-group>.<article-title> Exploring the link between nephrolithiasis and osteoporosis: implications for clinical management and treatment advancements.</article-title><source> International Urology and Nephrology</source>. <year>2025</year>; <volume>57</volume>: <fpage>2339</fpage>&#x2013;<lpage>2340</lpage>.</mixed-citation></ref>
<ref id="ref126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Farooq MU, Mustafa SH, Shah MT, Khan MJ, Iftikhar O</name></string-name></person-group>.<article-title> Dietary and fluid intake habits in nephrolithiasis patients presented to Ayub Teaching Hospital, Abbottabad.</article-title><source> International Journal of Scientific Reports</source>. <year>2018</year>; <volume>4</volume>: <fpage>274</fpage>&#x2013;<lpage>277</lpage>.</mixed-citation></ref>
<ref id="ref127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Dwivedi J, Sachan P, Wal P, Wal A, Rai AK</name></string-name></person-group>.<article-title> Current state and future perspective of diabetic wound healing treatment: present evidence from clinical trials.</article-title><source> Current Diabetes Reviews</source>. <year>2024</year>; <volume>20</volume>: <fpage>45</fpage>&#x2013;<lpage>65</lpage>.</mixed-citation></ref>
<ref id="ref128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Dwivedi J, Kumar P, Sachan P, Singh C, Saxena B, Wal A</name></string-name></person-group>, <italic>et al</italic>.<article-title> Phyto-pharmacological potential of aegle marmelos (L.) for neurological disorders: progress and prospects.</article-title><source> Recent Patents on Food, Nutrition &amp; Agriculture</source>. <year>2025</year>; <volume>16</volume>: <fpage>12</fpage>&#x2013;<lpage>30</lpage>.</mixed-citation></ref>
<ref id="ref129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Madore F, Stampfer MJ, Willett WC, Speizer FE, Curhan GC</name></string-name></person-group>.<article-title> Nephrolithiasis and risk of hypertension in women.</article-title><source> American Journal of Kidney Diseases</source>. <year>1998</year>; <volume>32</volume>: <fpage>802</fpage>&#x2013;<lpage>807</lpage>.</mixed-citation></ref>
<ref id="ref130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Seitz C, Fajkovic H</name></string-name></person-group>.<article-title> Epidemiological gender-specific aspects in urolithiasis.</article-title><source> World Journal of Urology</source>. <year>2013</year>; <volume>31</volume>: <fpage>1087</fpage>&#x2013;<lpage>1092</lpage>.</mixed-citation></ref>
<ref id="ref131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Pak CY, Sakhaee K, Crowther C, Brinkley L</name></string-name></person-group>.<article-title> Evidence justifying a high fluid intake in treatment of nephrolithiasis.</article-title><source> Annals of Internal Medicine</source>. <year>1980</year>; <volume>93</volume>: <fpage>36</fpage>&#x2013;<lpage>39</lpage>.</mixed-citation></ref>
<ref id="ref132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Bargagli M, Ferraro PM, Vittori M, Lombardi G, Gambaro G, Somani B</name></string-name></person-group>.<article-title> Calcium and vitamin D supplementation and their association with kidney stone disease: a narrative review.</article-title><source> Nutrients</source>. <year>2021</year>; <volume>13</volume>: <page>4363</page>.</mixed-citation></ref>
<ref id="ref133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Parivar F, Low RK, Stoller ML</name></string-name></person-group>.<article-title> The influence of diet on urinary stone disease.</article-title><source> The Journal of Urology</source>. <year>1996</year>; <volume>155</volume>: <fpage>432</fpage>&#x2013;<lpage>440</lpage>.</mixed-citation></ref>
<ref id="ref134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Moudi E, Ghaffari R, Moradi A</name></string-name></person-group>.<article-title> Pediatric nephrolithiasis: trend, evaluation and management: a systematic review.</article-title><source> Journal of Pediatrics Review</source>. <year>2017</year>; <volume>5</volume>: <fpage>11</fpage>&#x2013;<lpage>25</lpage>.</mixed-citation></ref>
<ref id="ref135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sun K, Zhao N, Shi P, Sun Z, Ye C, Fu L</name></string-name></person-group>, <italic>et al</italic>.<article-title> Early detection and monitoring of nephrolithiasis: the potential of electrochemical sensors.</article-title><source> Sensors</source>. <year>2025</year>; <volume>25</volume>: <page>2547</page>.</mixed-citation></ref>
<ref id="ref136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ticinesi A, Nouvenne A, Ferraro PM, Folesani G, Lauretani F, Allegri F</name></string-name></person-group>, <italic>et al</italic>.<article-title> Idiopathic calcium nephrolithiasis and hypovitaminosis D: a case-control study.</article-title><source> Urology</source>. <year>2016</year>; <volume>87</volume>: <fpage>40</fpage>&#x2013;<lpage>45</lpage>.</mixed-citation></ref>
<ref id="ref137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Mahajan K, Bhagat M, Cherukuri J, Gupta R, Sudershan A, Panjaliya RK</name></string-name></person-group>.<article-title> Identification and assessment of non-genetic factors contributing to nephrolithiasis (Kidney Stone) in the Jammu Region.</article-title><source> Biosciences Biotechnology Research Asia</source>. <year>2023</year>; <volume>20</volume>: <fpage>883</fpage>&#x2013;<lpage>895</lpage>.</mixed-citation></ref>
<ref id="ref138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Jazayeri SM, Mamaghani ME, Pourmoghaddam A, Azarfar A, Beni MH, Emam SJ</name></string-name></person-group>.<article-title> Need for emergent studies on dietary factors among infancy nephrolithiasis.</article-title><source> Archives of Italian Urology and Andrology</source>. <year>2011</year>; <volume>83</volume>: <fpage>133</fpage>&#x2013;<lpage>135</lpage>.</mixed-citation></ref>
<ref id="ref139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Dwivedi J, Wal P, Dash B, Ovais M, Sachan P, Verma V</name></string-name></person-group>.<article-title> Diabetic pneumopathy—a novel diabetes-associated complication: pathophysiology, the underlying mechanism and combination medication.</article-title><source> Endocrine, Metabolic &amp; Immune Disorders-Drug Targets</source>. <year>2024</year>; <volume>24</volume>: <fpage>1027</fpage>&#x2013;<lpage>1052</lpage>.</mixed-citation></ref>
<ref id="ref140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Mennuni G, Serio A, Fontana M, Nocchi S, Costantino C, Tanzi G</name></string-name></person-group>, <italic>et al</italic>.<article-title> Prevention and treatment of nephrolithiasis: a review on the role of spa therapy.</article-title><source> Clinical Therapeutics</source>. <year>2015</year>; <volume>166</volume>: <fpage>344</fpage>&#x2013;<lpage>356</lpage>.</mixed-citation></ref>
<ref id="ref141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Mossetti G, Rendina D, De Filippo G, Benvenuto D, Vivona CL, Zampa G</name></string-name></person-group>, <italic>et al</italic>.<article-title> Metabolic syndrome and nephrolithiasis: can we hypotize a common background? </article-title><source>Clinical Cases in Mineral and Bone Metabolism</source>. <year>2008</year>; <volume>5</volume>: <fpage>114</fpage>&#x2013;<lpage>117</lpage>.</mixed-citation></ref>
<ref id="ref142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Nackeeran S, Katz J, Ramasamy R, Marcovich R</name></string-name></person-group>.<article-title> Association between sex hormones and kidney stones: analysis of the National Health and Nutrition Examination Survey.</article-title><source> World Journal of Urology</source>. <year>2021</year>; <volume>39</volume>: <fpage>1269</fpage>&#x2013;<lpage>1275</lpage>.</mixed-citation></ref>
<ref id="ref143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Shabani E, Khorshidi A, Sayehmiri K, Moradi K, Abdolyousefi EN</name></string-name></person-group>.<article-title> The effect of nutritional factors on urolithiasis: a case-control study.</article-title><source> Journal of Medicine and Life</source>. <year>2023</year>; <volume>16</volume>: <fpage>1062</fpage>&#x2013;<lpage>1069</lpage>.</mixed-citation></ref>
<ref id="ref144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Donsimoni R, Hennequin C, Fellahi S, Troupel S, Le Moel G, Paris M</name></string-name></person-group>, <italic>et al</italic>.<article-title> New aspects of urolithiasis in France.</article-title><source> European Urology</source>. <year>1997</year>; <volume>31</volume>: <fpage>17</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation></ref>
<ref id="ref145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Akel M, Cherfan M, Safwan J, Sakr F, Dabbous M, Shamsedeen L</name></string-name></person-group>, <italic>et al</italic>.<article-title> An overview of kidney stone disease in Lebanon.</article-title><source> Global Journal of Pharmacology</source>. <year>2016</year>; <volume>10</volume>: <fpage>89</fpage>&#x2013;<lpage>97</lpage>.</mixed-citation></ref>
<ref id="ref146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Jungers P, Joly D, Barbey F, Choukroun G, Daudon M</name></string-name></person-group>.<article-title> ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention.</article-title><source> American Journal of Kidney Diseases</source>. <year>2004</year>; <volume>44</volume>: <fpage>799</fpage>&#x2013;<lpage>805</lpage>.</mixed-citation></ref>
<ref id="ref147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sakhaee K, Adams-Huet B, Moe OW, Pak CY</name></string-name></person-group>.<article-title> Pathophysiologic basis for normouricosuric uric acid nephrolithiasis.</article-title><source> Kidney International</source>. <year>2002</year>; <volume>62</volume>: <fpage>971</fpage>&#x2013;<lpage>979</lpage>.</mixed-citation></ref>
<ref id="ref148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>D’Alessandro C, Ferraro PM, Cianchi C, Barsotti M, Gambaro G, Cupisti A</name></string-name></person-group>.<article-title> Which diet for calcium stone patients: a real-world approach to preventive care.</article-title><source> Nutrients</source>. <year>2019</year>; <volume>11</volume>: <page>1182</page>.</mixed-citation></ref>
<ref id="ref149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Lertprapai C, Peerapen P, Thongboonkerd V</name></string-name></person-group>.<article-title> Effects of calcium oxalate crystals on neutrophil cellular proteome and functions: implications for nephrolithiasis.</article-title><source> Cell Communication and Signaling</source>. <year>2025</year>; <volume>23</volume>: <page>336</page>.</mixed-citation></ref>
<ref id="ref150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Pahira JJ</name></string-name></person-group>.<article-title> Nephrolithiasis: current concepts in medical management.</article-title><source> Urologic Radiology</source>. <year>1984</year>; <volume>6</volume>: <fpage>74</fpage>&#x2013;<lpage>79</lpage>.</mixed-citation></ref>
<ref id="ref151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Selvam R, Kalaiselvi P</name></string-name></person-group>.<article-title> Oxalate binding proteins in calcium oxalate nephrolithiasis.</article-title><source> Urological Research</source>. <year>2003</year>; <volume>31</volume>: <fpage>242</fpage>&#x2013;<lpage>256</lpage>.</mixed-citation></ref>
<ref id="ref152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Ferraro PM, Bargagli M, Trinchieri A, Gambaro G</name></string-name></person-group>.<article-title> Risk of kidney stones: influence of dietary factors, dietary patterns, and vegetarian–vegan diets.</article-title><source> Nutrients</source>. <year>2020</year>; <volume>12</volume>: <page>779</page>.</mixed-citation></ref>
<ref id="ref153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Hiatt RA, Ettinger B, Caan B, Quesenberry Jr CP, Duncan D, Citron JT</name></string-name></person-group>.<article-title> Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones.</article-title><source> American Journal of Epidemiology</source>. <year>1996</year>; <volume>144</volume>: <fpage>25</fpage>&#x2013;<lpage>33</lpage>.</mixed-citation></ref>
<ref id="ref154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Turney BW, Appleby PN, Reynard JM, Noble JG, Key TJ, Allen NE</name></string-name></person-group>.<article-title> Diet and risk of kidney stones in the Oxford cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC).</article-title><source> European Journal of Epidemiology</source>. <year>2014</year>; <volume>29</volume>: <fpage>363</fpage>&#x2013;<lpage>369</lpage>.</mixed-citation></ref>
<ref id="ref155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sofia NH, Walter TM, Sanatorium T</name></string-name></person-group>.<article-title> Prevalence and risk factors of kidney stone.</article-title><source> Global Journal for Research Analysis</source>. <year>2016</year>; <volume>5</volume>: <fpage>183</fpage>&#x2013;<lpage>187</lpage>.</mixed-citation></ref>
<ref id="ref156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Nouvenne A, Ticinesi A, Morelli I, Guida L, Borghi L, Meschi T</name></string-name></person-group>.<article-title> Fad diets and their effect on urinary stone formation.</article-title><source> Translational Andrology and Urology</source>. <year>2014</year>; <volume>3</volume>: <fpage>303</fpage>&#x2013;<lpage>312</lpage>.</mixed-citation></ref>
<ref id="ref157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Sachan P, Shrivastava P, Goswami M</name></string-name></person-group>.<article-title> Revolutionizing the potential of probiotics an evidence-based review.</article-title><source> Journal of Ravishankar University</source>. <year>2024</year>; <volume>37</volume>: <fpage>60</fpage>&#x2013;<lpage>79</lpage>.</mixed-citation></ref>
<ref id="ref158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Rodgers AL, Lewandowski S</name></string-name></person-group>.<article-title> Effects of 5 different diets on urinary risk factors for calcium oxalate kidney stone formation: evidence of different renal handling mechanisms in different race groups.</article-title><source> The Journal of Urology</source>. <year>2002</year>; <volume>168</volume>: <fpage>931</fpage>&#x2013;<lpage>936</lpage>.</mixed-citation></ref>
<ref id="ref159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Robertson WG</name></string-name></person-group>.<article-title> Dietary recommendations and treatment of patients with recurrent idiopathic calcium stone disease.</article-title><source> Urolithiasis</source>. <year>2016</year>; <volume>44</volume>: <fpage>9</fpage>&#x2013;<lpage>26</lpage>.</mixed-citation></ref>
<ref id="ref160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Barghouthy Y, Corrales M, Somani B</name></string-name></person-group>.<article-title> The relationship between modern fad diets and kidney stone disease: a systematic review of literature.</article-title><source> Nutrients</source>. <year>2021</year>; <volume>13</volume>: <page>4270</page>.</mixed-citation></ref>
<ref id="ref161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Boarin M, Villa G, Capuzzi C, Remon D, Abbadessa F, Manara DF</name></string-name></person-group>.<article-title> Dietary and lifestyle recommendations for urolithiasis prevention: a systematic literature review.</article-title><source> International Journal of Urological Nursing</source>. <year>2018</year>; <volume>12</volume>: <fpage>53</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="ref162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><name>Kok DJ</name></string-name></person-group>.<article-title> The preventive treatment of recurrent stone-formation: how can we improve compliance in the treatment of patients with recurrent stone disease? </article-title><source>Urolithiasis</source>. <year>2016</year>; <volume>44</volume>: <fpage>83</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation></ref>
 
	
   </ref-list>  
     
 </back> 
</article> 
